View Future GrowthelectroCore 過去の業績過去 基準チェック /06electroCoreは9%の年平均成長率で業績を伸ばしているが、Medical Equipment業界はgrowingで7.5%毎年増加している。売上は成長しており、年平均39.1%の割合である。主要情報9.01%収益成長率27.50%EPS成長率Medical Equipment 業界の成長4.25%収益成長率39.07%株主資本利益率n/aネット・マージン-39.96%前回の決算情報30 Jun 2026最近の業績更新Reported Earnings • 21hSecond quarter 2026 earnings released: US$0.33 loss per share (vs US$0.44 loss in 2Q 2025)Second quarter 2026 results: US$0.33 loss per share (improved from US$0.44 loss in 2Q 2025). Revenue: US$9.45m (up 28% from 2Q 2025). Net loss: US$3.06m (loss narrowed 17% from 2Q 2025). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany.お知らせ • Jul 30electroCore, Inc. to Report Q2, 2026 Results on Aug 06, 2026electroCore, Inc. announced that they will report Q2, 2026 results After-Market on Aug 06, 2026お知らせ • Apr 29electroCore, Inc. to Report Q1, 2026 Results on May 06, 2026electroCore, Inc. announced that they will report Q1, 2026 results After-Market on May 06, 2026お知らせ • Mar 09electroCore, Inc. to Report Q4, 2025 Results on Mar 19, 2026electroCore, Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026お知らせ • Oct 23electroCore, Inc. to Report Q3, 2025 Results on Nov 05, 2025electroCore, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2025お知らせ • Jul 23electroCore, Inc. to Report Q2, 2025 Results on Aug 06, 2025electroCore, Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025すべての更新を表示Recent updatesReported Earnings • 21hSecond quarter 2026 earnings released: US$0.33 loss per share (vs US$0.44 loss in 2Q 2025)Second quarter 2026 results: US$0.33 loss per share (improved from US$0.44 loss in 2Q 2025). Revenue: US$9.45m (up 28% from 2Q 2025). Net loss: US$3.06m (loss narrowed 17% from 2Q 2025). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany.お知らせ • 22hElectrocore, Inc. Increases Earnings Guidance for the Full Year 2026electroCore, Inc. increased earnings guidance for the full year 2026. For the period, the company expects revenue guidance to greater than 30% annual growth over full-year 2025.Breakeven Date Change • Aug 07The 5 analysts covering electroCore previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 54% per year to 2027. The company is expected to make a profit of US$4.62m in 2028. Average annual earnings growth of 88% is required to achieve expected profit on schedule.お知らせ • Jul 30electroCore, Inc. to Report Q2, 2026 Results on Aug 06, 2026electroCore, Inc. announced that they will report Q2, 2026 results After-Market on Aug 06, 2026お知らせ • Jul 21electroCore, Inc., Annual General Meeting, Sep 08, 2026electroCore, Inc., Annual General Meeting, Sep 08, 2026.Recent Insider Transactions • May 29Founder & Independent Chairman recently bought €52k worth of stockOn the 21st of May, Thomas Errico bought around 10k shares on-market at roughly €5.17 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Thomas has been a buyer over the last 12 months, purchasing a net total of €109k worth in shares.New Risk • May 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.9m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$5.7m). Minor Risks Significant insider selling over the past 3 months (€82k sold). Market cap is less than US$100m (€63.6m market cap, or US$73.9m).お知らせ • May 15electroCore, Inc. Announces Publication in JAMA Highlighting Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in FibromyalgiaelectroCore, Inc. announced the publication of new clinical findings in JAMA Network Open titled, Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial. The study evaluated the use of a modified Quell device, an FDA-authorized nonpharmacological wearable stimulation device, when added to outpatient physical therapy (“PT”) for people with fibromyalgia. The trial enrolled 384 participants [that completed baseline data collection], including 191 individuals in the PT-Quell group and 193 individuals in the PT-only group. At day 60, reduction in movement-evoked pain was significantly greater in the PT-Quell group compared with the PT-only group, (between-group difference, -1.2 points [95% CI, -1.6 to -0.7]; P<.001), and statistically significant improvements favoring the PT-Quell group were also observed across several other secondary measures, including resting pain, pain interference, movement-evoked fatigue, resting fatigue, and fibromyalgia impact (FIQR) during the randomized phase. The benefits of Quell were observed within 30 days and were sustained for up to six months. Among respondents, 81% reported finding Quell helpful, and 55% continued to use Quell daily.お知らせ • Apr 29electroCore, Inc. to Report Q1, 2026 Results on May 06, 2026electroCore, Inc. announced that they will report Q1, 2026 results After-Market on May 06, 2026お知らせ • Apr 09Electrocore Inc Announces First Patient Enrollment in Investigator-Led Study of Gammacore nVNS for PTSDElectroCore, Inc. announced the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society. The study is designed to evaluate the safety and effectiveness of electroCore’s gammaCore non-invasive vagus nerve stimulation (nVNS) device as an adjunctive treatment for symptoms associated with PTSD. The study is expected to enroll up to 40 adult participants and will assess outcomes over a 12-week treatment period. The primary safety endpoint is the incidence of treatment-related serious adverse events, and the primary efficacy endpoint is the change from baseline in the Clinician-Administered PTSD Scale (CAPS-5) total score at 12 weeks. Secondary endpoints include changes in PTSD Checklist (PCL-5) scores and Clinical Global Impression (CGI) ratings. The study is sponsored by the Vagus Nerve Society, with electroCore providing an educational grant and gammaCore devices. The study is anticipated to run for approximately 10 months and is intended to generate preliminary safety and effectiveness data to inform future research in neuropsychiatric applications of nVNS.お知らせ • Apr 01ElectroCore Inc Announces Publication Highlighting Benefits Of Non-Invasive Vagus Nerve Stimulation In Patients With Mild Traumatic Brain Injury And PTSDElectroCore, Inc. announced the publication of new clinical findings in Frontiers in Neuroscience titled “Adjunctive non-invasive vagus nerve stimulation for chronic mild traumatic brain injury with comorbid post-traumatic stress disorder: a post-hoc analysis” by Drs. Michael Ament, Peter Staats, Norianne Theresa Ingram, and Emily Leonard, demonstrating the potential benefits of adjunctive non-invasive vagus nerve stimulation (nVNS) in patients with chronic mild traumatic brain injury (mTBI) and comorbid post-traumatic stress disorder (PTSD). The publication reports results from a post-hoc analysis of 35 patients with chronic mTBI and PTSD. The analysis showed that adjunctive nVNS significantly reduced overall symptom burden, with observed improvements across cognitive, affective, and somatic domains. The study population represented a high-symptom-burden cohort commonly associated with persistent and difficult-to-treat neurobehavioral symptoms. The full article can be accessed here: Frontiers: nVNS for mTBI and PTSD. These findings contribute to the growing body of evidence supporting the therapeutic potential of nVNS in patients with chronic mTBI and comorbid PTSD.お知らせ • Mar 20+ 2 more updateselectroCore, Inc. Provides Revenue Guidance for the Full Year of 2026electroCore, Inc. provided revenue guidance for the full year of 2026. For the period, the company expects revenue of approximately 30% annual revenue growth over 2025.お知らせ • Mar 09electroCore, Inc. to Report Q4, 2025 Results on Mar 19, 2026electroCore, Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026お知らせ • Jan 21electroCore, Inc. Provides Earnings Guidance for the Fourth Quarter and Year Ended December 31, 2025electroCore, Inc. provided earnings guidance for the fourth quarter and year ended December 31, 2025. The company anticipated reporting fourth quarter 2025 revenue is anticipated to be approximately $9.0 - $9.2 million, which would represent approximately 30% growth over fourth quarter of 2024. The company anticipated reporting record full year 2025 revenue of approximately $31.8 - $32.0 million. This would represent approximately 26% growth over full-year 2024 revenue of $25.2 million.お知らせ • Oct 23electroCore, Inc. to Report Q3, 2025 Results on Nov 05, 2025electroCore, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2025お知らせ • Oct 18electroCore, Inc. announced that it has received $1.856 million in fundingOn October 17, 2025, electroCore, Inc closed the transaction. the transaction included participation from 3 Investors.お知らせ • Oct 02electroCore, Inc. Announces the Publication of A Peer-Reviewed Study in Frontiers in Neurology Demonstrating the Effectiveness of gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) in Reducing Persistent Post-Concussion SymptomselectroCore, Inc. announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). The article, entitled "Non-invasive vagus nerve stimulating is associated with the reduction in persistent post-concussion symptoms: an observational study," found that adjunctive use of gammaCore with standard care was associated with significant and clinically meaningful improvements across multiple domains of the Neurobehavioral Symptom Inventory (NSI). The study included 102 patients with persistent symptoms following mTBI. Patients experienced significant reductions in 16 of 22 symptom categories, including post-traumatic headache, dizziness, difficulty concentrating, and depression. Approximately 34% of patients reported meaningful improvement in at least half of their persistent symptoms. Importantly, improvements were observed both in patients treated within three months of injury and in those whose symptoms had persisted for over a year, suggesting that nVNS may be beneficial regardless of time since injury.お知らせ • Sep 30electroCore Announces Reimbursement Approval for gammaCore by RIZIV/INAMI in BelgiumelectroCore, Inc. announced that gammaCore Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV /INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clinical evidence supporting the therapy's efficacy and cost-effectiveness and ensures broader access for Belgian patients. This achievement was made possible through the leadership and commitment of Silvert Medical, electroCore's distribution partner in Belgium. Silvert Medical leveraged their local expertise and strong provider relationships, playing a key role in securing reimbursement. Silvert Medical remains a vital partner in supporting the rollout of gammaCore in Belgium and is committed to extending access to gammaCore in neighboring countries.お知らせ • Sep 05electroCore, Inc. Announces Management ChangeselectroCore, Inc. announced the departure of Peter Cuneo from the Board of Directors and that Thomas J. Errico, MD, has been elected to succeed Mr. Cuneo as Chairman of the Board, effective September 2, 2025. Mr. Cuneo will continue as a strategic advisor to the Company.お知らせ • Sep 04electroCore, Inc. Announces Board ChangeselectroCore, Inc. announced that Elena Bonfiglioli, an accomplished healthcare executive, has been appointed to electroCore’s Board of Directors, effective September 2, 2025. Ms. Bonfiglioli’s appointment follows the retirement from the Board of Peter Cuneo. Ms. Bonfiglioli has been working in the health sector for more than two decades. She currently serves as Microsoft’s Global Business Leader for Healthcare, Pharma Life Sciences, and the International clinical applications’ solutions, responsible for go-to-market, commercial, and partnerships, enabling artificial intelligence (“AI”) transformation initiatives in health providers, payors and Life Sciences’ organizations globally. Since 2023, Ms. Bonfiglioli has been a Member of the Drug Information Association (“DIA”) for Europe, Middle East & Africa Regional Advisory Council, and serves as a board member of several startups in Europe and the Middle East and as advisor for biopharma organizations. Ms. Bonfiglioli was selected twice as one of the top 50 AI Innovators by Intelligent Health and was one of the founding members of the Holomedicine Association; and Vice Chair of the DIGITALEUROPE Executive Council for Healthcare since its creation in 2021. Ms. Bonfiglioli was a champion for secondary use of data to enhance research and activate the power of data to save lives. She recently joined the Board of The Women Health Initiative, a community powered by Kearney. She is active in the field of longevity and champions the shift to health enhanced by data and AI.お知らせ • Aug 12electroCore, Inc. Announces Appointment of Kelly Benning as Senior Vice President of Truvaga, Effective July 21, 2025electroCore, Inc. announced that Kelly Benning has been hired as the Senior Vice President of Truvaga, effective July 21, 2025.Ms. Benning, who brings almost three decades of leadership experience across digital health, AI-enabled technologies, and consumer wellness, will lead electroCore’s consumer wellness division. Ms. Benning has successfully brought pioneering digital health products to market, including the first and only FDA-cleared watch to monitor blood pressure, delivering breakthrough solutions and expertly navigating the commercialization process. Her interest in AI and machine-learning has led her to drive continual innovation and consistent market adoption of technology at the intersection of healthcare, data, and consumer experience.Throughout her career, Ms. Benning has worked with a multitude of consumer retailers, payors, providers, and healthcare enterprises to bring clinically impactful and commercially successful products to market. She currently serves as Senior Vice President of Truvaga, electroCore’s digital wellness platform, where she leads strategy, operations, and growth. Prior to joining electroCore, Ms. Benning held executive leadership roles including President at LiveMetric, Vice President of Sales at IBM Watson Health, and senior roles at CipherHealth, Savonix, Healthgrades, and National Jewish Health. Ms. Benning holds a Bachelor of Arts in Kinesiology and Exercise Science from the University of Colorado Boulder.お知らせ • Aug 09electroCore, Inc Provides Earnings Guidance for the Full Year 2025electroCore, Inc. provided earnings guidance for the full year 2025. for the year, the company expects total revenue to be approximately $30.0 million and net cash usage for the remainder of the year to be between approximately $3.9 and $4.4 million.お知らせ • Aug 06electroCore, Inc. Appoints James C. Theofilos to its Board of Directors, Effective August 1, 2025electroCore, Inc. announced that James C. Theofilos has been appointed to the Board of Directors, effective August 1, 2025. Mr. Theofilos has been a Senior Finance Manager within the Azure and artificial intelligence division of Microsoft Corporation since October 2023. In this role, Mr. Theofilos is the Go-to-Market Finance Lead across Microsoft’s AI Apps & Agents team, which includes all of Microsoft’s AI models, GitHub Copilot, Copilot Studio, and other products that aim to deliver the full value of AI & Agents. Previously, Mr. Theofilos held various finance positions at Microsoft including his position as the Finance Lead for Microsoft’s Global Healthcare & Life Sciences Sales team, which included exposure to the Health Providers, Payors, Pharma and Med Tech industry verticals. Prior to that, Mr. Theofilos consulted as a Group Project Manager at VICI Properties Inc. Mr. Theofilos holds an M.S. in Finance and a B.S.B.A. in Finance from Washington University in Saint Louis.お知らせ • Jul 23electroCore, Inc. to Report Q2, 2025 Results on Aug 06, 2025electroCore, Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025お知らせ • Jul 18electroCore, Inc., Annual General Meeting, Sep 02, 2025electroCore, Inc., Annual General Meeting, Sep 02, 2025.お知らせ • May 16Happy Holstein Management, LLC Provides Information to the electroCore, Inc.On May 14, 2025, Happy Holstein Management, LLC announced that they are evaluating the feasibility of a change in the present board of directors or management of electroCore, Inc, including plans or proposals to nominate one or more director candidates, to amend the Company's charter and bylaws to remove the classified board, and other proposals to improve the corporate governance and transparency at the Company. Consistent with their investment purpose and subject to any applicable confidentiality obligations, one or more Happy Holstein Management, LLC or their representatives may engage in communications regarding the Company with other persons, including, without limitation, one or more shareholders of the Company, one or more officers of the Company and/or one or more members of the Board of Directors of the Company.お知らせ • May 08electroCore, Inc. Provides Preliminary Revenue Guidance for Year Ending December 2025electroCore, Inc. provided preliminary revenue guidance for year ending December 2025. For the year, the company expects total revenue to be approximately $30.0 million.お知らせ • Apr 30electroCore, Inc. to Report Q1, 2025 Results on May 07, 2025electroCore, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025お知らせ • Mar 06electroCore, Inc. to Report Q4, 2024 Results on Mar 12, 2025electroCore, Inc. announced that they will report Q4, 2024 results After-Market on Mar 12, 2025お知らせ • Mar 01electroCore, Inc. Announces Resignation of Charles S. Theofilos as A Class III Director of the Board, as A Member of the Compensation Committee of the Board, and as A Member of the Nominating and Governance CommitOn February 24, 2025, Charles S. Theofilos, M.D., a member of the Board of Directors of electroCore, Inc. resigned as a Class III director of the Board, as a member of the Compensation Committee of the Board, and as a member of the Nominating and Governance Committee of the Board, in each case effective immediately. In connection with Dr. Theofilos’ resignation, on February 28, 2025, the Board decreased the size of the Board from eight to seven members, effective immediately.お知らせ • Jan 25electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Dec 18electroCore, Inc. (NasdaqCM:ECOR) entered into an agreement and plan of merger to acquire NeuroMetrix, Inc. (NasdaqCM:NURO).electroCore, Inc. (NasdaqCM:ECOR) entered into an agreement and plan of merger to acquire NeuroMetrix, Inc. (NasdaqCM:NURO) on December 17, 2024. At the effective time of the Merger (the “Effective Time”), each share of common stock, par value $0.0001 per share, of the Company (the “Company Common Stock”) outstanding immediately prior to the Effective Time, shall be cancelled and cease to exist and shall be converted into the right to receive (i) an amount in cash (the “Per Share Cash Consideration’) equal to a pro rata share of the Company’s balance of Net Cash (as determined pursuant to the Merger Agreement) at the Effective Time, after deduction of certain pro rata payments that will be due in accordance with the MRIP (as defined below), without interest and (ii) one contingent value right (a “CVR"), which shall represent the right to receive the Contingent Payments (as defined below) subject to the terms and conditions set forth in the CVR Agreement. Under the terms of the merger agreement, a subsidiary of electroCore will merge with NeuroMetrix and NeuroMetrix will become a wholly owned subsidiary of electroCore. Upon termination of the Merger Agreement under specified circumstances, the NeuroMetrix will be required to pay electroCore a termination fee of $500,000. Consummation of the Merger is subject to customary closing conditions, including, without limitation, the absence of certain legal impediments, the approval by the holders of a majority of the outstanding shares of NeuroMetrix Common Stock entitled to vote on the Merger, the determination of Net Cash pursuant to the Merger Agreement, and the filing by the NeuroMetrix of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close late in the first quarter of 2025. Ira Kotel and Ilan Katz of Dentons US LLP acted as legal advisors to electroCore. Megan Gates of Covington& Burling LLP acted as legal advisor to NeuroMetrix in the transaction.お知らせ • Nov 30electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Oct 23electroCore, Inc. to Report Q3, 2024 Results on Nov 13, 2024electroCore, Inc. announced that they will report Q3, 2024 results After-Market on Nov 13, 2024お知らせ • Jul 31electroCore, Inc. to Report Q2, 2024 Results on Aug 07, 2024electroCore, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024お知らせ • Jul 18electroCore, Inc., Annual General Meeting, Sep 03, 2024electroCore, Inc., Annual General Meeting, Sep 03, 2024.お知らせ • Jun 26electroCore Announces the Commercial Launch of TAC-STIM™?electroCore, Inc. announced the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM™?, a non-invasive vagus nerve stimulator (nVNS) designed in partnership with the US military to enhance human performance exclusively for active-duty military use. TAC-STIM is a cutting-edge device that can accelerate learning and improve mood and cognitive performance. TAC-STim is a portable, easy-to-use tool that leverages electroCore's patented technology to deliver precise and effective vagus nerve stimulation, helping war fighters and operators learn new tasks, increase readiness and mitigate fatigue across a range of high-pressure operational environments. TAC-STIM was originally developed in close collaboration with the 711th Human Performance Wing at the Air Force Research Laboratory (AFRL), Wright-Patterson AFB, OH, as part of the United States Department of Defense Biotech Optimized for Operational Solutions and tactics (BOOST) program. Independent testing by AFRL and Air Force Special Operations Command consistently demonstrated its capabilities across a range of operational settings. electroCore continues to participate in collaborative research to further enhance TAC-STIMs operational utility and showcase how TAC-STIM can enhance performance, reduce fatigue, and accelerate training without adverse effects. Key benefits of TAC-STIM include: Improve performance and combat fatigue for 12-24 hours under extreme conditions; 20-35% faster learning of complex material; Enhance ability to multi-task; Significantly decreased fatigue and increased focus.お知らせ • Jun 08+ 1 more updateelectroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million.electroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million. Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 225,000 Price\Range: $6.429 Transaction Features: Registered Direct Offeringお知らせ • Jun 05+ 1 more updateelectroCore, Inc. announced a financing transactionelectroCore, Inc. announced a private placement of 1,208,310 common shares and warrants on June 3, 2024. The warrants can be exercisable into an aggregate of 604,150 shares of common stock. The transaction is expected to close on June 5, 2024.お知らせ • May 06electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and ComplianceelectroCore, Inc. announced that on May 1, 2024, Donald Melnikoff joined electroCore as the Company’s SVP, Engineering, Regulatory, and Compliance; the Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Melnikoff in connection with the commencement of his employment.お知らせ • May 03electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024electroCore, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024お知らせ • Apr 30electroCore, Inc. Announces Results of Truvaga Plus Consumer StudyelectroCore, Inc. announced the results of its most recent Truvaga Plus consumer study conducted earlier this year. Based on a 30-day in-home use test by an independent third-party research firm, Truvaga Plus helped its users improve sleep, focus, stress, energy, and mood. 39 participants were instructed to use the Truvaga Plus product at home twice a day for 30 days to assess the product's benefits, efficacy, and overall user experience. Self-assessment evaluations were reported after 7 and 30 days. After 30 days, users reported the following: 82% felt calmer; 82% felt mentally healthier; 77% felt more alert; 77% felt more relaxed; 74% felt they sleep better; 74% felt their mood improved; and 67% had more energy. Of those that felt they slept better, 72% reported they received between 30 minutes to 2+ hours or more sleep each night. After the study completed, 87% of users said they were likely to continue to use Truvaga Plus for ongoing overall wellness benefits.お知らせ • Apr 10electroCore, Inc. Announces the Launch of Truvaga Plus® for General WellnesselectroCore, Inc. announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024. Key features of Truvaga Plus include: Mobile App Connectivity: Empowering users to control sessions, plan schedules, and track progress conveniently through integrated mobile application. Unlimited Sessions: Providing users with the flexibility for prolonged usage and extended benefits, ensuring continuous support for achieving optimal wellness. Rechargeable: Enhancing sustainability and user convenience, Truvaga Plus features a rechargeable design for uninterrupted usage. Compact Design: Sleeker, smaller, and more portable, the new design of Truvaga Plus ensures enhanced user comfort and convenience.お知らせ • Mar 06electroCore, Inc. to Report Q4, 2023 Results on Mar 13, 2024electroCore, Inc. announced that they will report Q4, 2023 results After-Market on Mar 13, 2024お知らせ • Dec 15electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the BoardOn December 8, 2023, the board of directors (the “ Board”) of electroCore, Inc. (the “ Company”) appointed Charles S. Theofilos, M.D., as a new Class III member of the Board. The term of each Class III director lasts until the Company’s 2024 annual meeting of stockholders. In connection with the appointment of Dr. Theofilos to the Board, the size of the Board was increased by resolution of the Board from seven members to eight members on December 8, 2023. Dr. Theofilos is a retired neurosurgeon who founded The Spine Center in Palm Beach Gardens, FL in 1996. He also founded and serves as President of Theo Concepts, LLC and Founder of The Theo Group, a family office. Previously, he served as Co-Director of the Neuroscience Center, Chairman of Neurosurgery, and Chairman of Cranial and Spinal Surgery, at JFK Medical Center in Atlantis, Florida, Director of Spine Surgery at Jupiter Medical Center, and Chairman of Neurosurgery at Palm Beach Gardens Medical Center. Dr. Theofilos has been a founder, director and/or investor in a number of early-stage medical device and healthcare companies, including K2Medical, SpineCore LLC and electroCore, LLC, a predecessor of the Company. Dr. Theofilos received an M.D. from Emory University School of Medicine, a B.A. in biology from Emory University, and a GMP (General Management Program) from The Wharton School of The University of Pennsylvania.お知らせ • Oct 26Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation (Nvns) for Treatment of Symptoms of GastroparesiselectroCore, Inc. announced top line data from an abstract being presented as an oral podium presentation at the 2023 American College of Gastroenterology Annual Meeting held in Vancouver, Canada from October 23- 25, 2023 regarding the potential for nVNS to decrease the use of acute rescue medications for exacerbations of nausea due to Gastroparesis (GP) or Functional Dyspepsia (FD). Many gastrointestinal disorders can cause nausea and vomiting, of which the most well-known is gastroparesis, a digestive disorder in which the stomach empties slowly. The symptoms of gastroparesis can range from mild to severe, requiring prolonged hospitalizations and interventions, and causing life-threatening complications which can significantly affect the quality of life in affected individuals. It is estimated that close to 6 million Americans suffer from gastroparesis which is more common in women than men. The economic impact of gastroparesis can be substantial, with studies reporting 11% of patients disabled due to their gastroparesis symptoms, while another 28.5% reported a loss of yearly income. Nausea without slow gastric emptying may be even more common and has been referred to by many names, including chronic unexplained nausea and vomiting (CUNV), gastroparesis-like syndrome (GLS), functional vomiting, and vomiting of unexplained etiology (VUE). Many of these patients can be classified as having functional dyspepsia (FD) which is a disorder that may affect 10% of the US population. Non-Invasive Vagal Nerve Stimulation (nVNS) Reduces Nausea Rescue Medication in Patients with Gastroparesis andRelated Disorders, with Additional Benefits on Multiple Other Associated Symptoms This pilot study (n=41) included patients =15 years of age with ongoing GP or FD symptoms for a period of =3 months. The focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.お知らせ • Oct 10electroCore, Inc. to Report Q3, 2023 Results on Nov 08, 2023electroCore, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023お知らせ • Sep 28electroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress DisorderelectroCore, Inc. announced the publication of two peer reviewed publications supporting the use of gammaCore (non-invasive vagal nerve stimulation; nVNS) in patients with posttraumatic stress disorder (PTSD). The first paper entitled "Effect of transcutaneous cervical vagus nerve stimulation on declarative and working memory in patients with Posttraumatic Stress Disorder (PTSD): A pilot study" wasauthored by Tilendra Choudhary and the second, "Transcutaneous vagal nerve stimulation modulates stress-induced plasma ghrelin levels: A double-blind, randomized, sham-controlled trial" was written by Kasra Moazzami. Both studies were conducted at Emory University and were published in the peer reviewed Journal of Affective Stress Disorder. The prevalence of PTSD in the United States is estimated at 10-12% in women and 5-6% in men, and the prevalence in veterans can be twice as high. Ghrelin is a neuropeptide hypothesized to be involved in the stress response but also plays an important role in the regulation of appetite. Biomarkers that can be easily assessed can help identify likely responders to a specific therapy and are critical to improving the patient experience and decreasing health care costs. The results of this study showed that TCVNS, in conjunction with personalized traumatic scripts, resulted in lower ghrelin levels (265.2 +- 143.6 pg/ml vs 478.7 +- 349.2 pg/ml, P = 0.01). Additionally, after completing the public speaking and mental math tests, ghrelin levels were found to be lower in the group receiving TCVNS (293.3 +- 102.4 pg/ml vs 540.3 +- 203.9 pg/ml, P =0.009).2 Ghrelin may be involved in behaviors like stress-induced over-eating, suggesting future avenues of research into the potential for nVNS in the treatment of obesity and possibly stress-induced eating disorders.お知らせ • Aug 24electroCore, Inc. Announces Dismissal of All Litigation Related to Its 2018 Initial Public OfferingelectroCore, Inc. announced that it has been completely vindicated in the securities class actions over the company’s 2018 initial public offering brought in the federal and state courts of New Jersey. The litigation has concluded without any finding of wrongdoing or liability, nor any payment, by electroCore. On July 13, 2023, District Judge Zahid N. Quraishi of the United States District for the District of New Jersey, dismissed the second amended class action complaint alleging violations of the Securities Act and the Securities Exchange Act. In a detailed opinion, Judge Quraishi considered each of the plaintiff’s allegations of misrepresentations and omissions in the prospectus for the IPO and in other public statements and filings in 2018-19 and held the plaintiff has not adequately pleaded any alleged untrue statement or that any allegedly omitted information rendered any factual statement untrue. Judge Quraishi also found that the plaintiff failed to adequately allege that electroCore intended to mislead or omit information. Judge Quraishi permitted the plaintiff thirty days to try to amend their complaint for a third time but warned that “while the Plaintiff can change the words of the Complaint, Plaintiff cannot change the words of the Prospectus.” Judge Quraishi’s dismissal followed the prior dismissal of the first amended complaint, also in a detailed opinion assessing each of plaintiff’s allegations, by District Judge Anne E. Thompson, on August 13, 2021. The plaintiff decided not to amend their complaint a third time and did not appeal the District Court’s ruling within the required time. Thus, the federal court litigation is over. This follows the termination earlier this year of litigation over the IPO and electroCore’s statements initiated in 2019 in the Somerset County, New Jersey Superior Court. That case was twice dismissed with prejudice, and on May 15, 2023, the Appellate Division of the New Jersey Superior Court unanimously affirmed the dismissal with prejudice. The time for further appeals in that case also has expired. Thus, the litigation over the initial public offering has been brought to a close with a complete vindication of electroCore, its directors and its management in their handling of the 2018 IPO.お知らせ • Aug 11electroCore, Inc. Reiterates Revenue Guidance for the Year 2023electroCore, Inc. reiterated revenue guidance for the year 2023. The company reiterates its revenue guidance of $14.0 million to $15.0 million for calendar year 2023.お知らせ • Aug 03electroCore, Inc. to Report Q2, 2023 Results on Aug 09, 2023electroCore, Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023お知らせ • Jul 12Electrocore Provides Earnings Guidance for the Second Quarter and Full Fiscal Year 2023electroCore Provided earnings guidance for the Second Quarter and full fiscal year 2023 . For the quarter, Company,anticipates reporting record quarterly revenue of approximately $3,550,000 for the quarter ended June 30, 2023. This would represent approximately 65% growth over second quarter 2022 revenue of approximately $2,157,000For the year, Company reiterated its revenue guidance of $14.0 Million -$15.0 Million.お知らせ • Jun 06electroCore, Inc., Annual General Meeting, Aug 04, 2023electroCore, Inc., Annual General Meeting, Aug 04, 2023, at 09:00 US Eastern Standard Time. Agenda: To elect one Class II director to the Board for a three-year term of office expiring at the 2026 Annual Meeting of Stockholders; and to ratify the selection of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.お知らせ • May 05electroCore, Inc. Reiterates Revenue Guidance for the Year Ending December 31, 2023electroCore, Inc. reiterated revenue guidance for the year ending December 31, 2023. The Company reiterated its revenue guidance of $14.0 million to $15.0 million for the year ending December 31, 2023.お知らせ • Jan 18electroCore, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2022electroCore, Inc. provided preliminary earnings guidance for the fourth quarter and full year of 2022. For the year, the company anticipates reporting record full year 2022 revenue of approximately $8.5 million. This would represent approximately 57% growth over full-year 2021 revenue of $5.5 million.For the quarter, the company's revenue is anticipated to be approximately $2.5 million, which would represent approximately 68% growth over fourth quarter of 2021.お知らせ • Dec 26electroCore Receives a Determination Letter from Nasdaq Regarding Minimum Bid PriceOn December 20, 2022, electroCore, Inc. (the “Company”), received a determination letter (the “Letter”) from the staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company’s common stock, par value $0.001 per share (the “Common Stock”), has not achieved a minimum bid price of $1.00 per share for a minimum of 10 consecutive trading days, as required for continuing listing of the Common Stock on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The Company intends to timely request an appeal hearing before a Nasdaq Hearings Panel (the “Panel”). While the appeal process is pending, the potential suspension of trading of the Common Stock by Nasdaq will be stayed, a Form 25-NSE will not be filed with the Securities and Exchange Commission (the “SEC”), and the Common Stock will continue to trade on the Nasdaq Capital Market until the hearing process concludes and the Panel issues a written decision. The Company expects to be asked to furnish the Panel with a plan to regain compliance. As part of such plan, the Company is prepared to pursue stockholder authorization of a reverse stock split and make other commitments as necessary to regain compliance with the Bid Price Rule in order to avoid delisting of the Common Stock from the Nasdaq Capital Market. Pursuant to the Letter, if the Company does not timely request a hearing by 4:00 p.m. Eastern Time on December 27, 2022, the Common Stock will be delisted from the Nasdaq Capital Market, trading of the Common Stock will be suspended at the opening of business on December 29, 2022, and a Form 25-NSE will be filed with the SEC, which will remove the Common Stock from listing and registration on Nasdaq. There can be no assurance that the Panel will grant the Company’s request for a suspension of delisting or continued listing on the Nasdaq Capital Market. If the Common Stock ceases to be listed for trading on the Nasdaq Capital Market, the Company expects the Common Stock would be traded on one of the marketplaces of the OTC Markets Group. On December 23, 2022, the Company filed a definitive proxy statement on Schedule 14A with the SEC relating to a special meeting (the “ Special Meeting”) of stockholders of the Company currently scheduled to be held on February 13, 2023, at which the stockholders will consider and vote on a proposal to authorize the Board, in its discretion, to effect a reverse stock split of the Common Stock (the “ Reverse Stock Split Proposal”). The reverse stock split will not be effective unless and until the stockholders approve the Reverse Stock Split Proposal, and unless and until an amendment to the Company’s certificate of incorporation, as amended, to effect the reverse stock split is filed with the Secretary of State of the State of Delaware. There can be no assurance that the Company will not be delisted from Nasdaq before or after the stockholders have the opportunity at the Special Meeting to approve the Reverse Stock Split Proposal.お知らせ • Dec 21electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, TruvagaelectroCore, Inc. announced the launch of a new wellness product offering called Truvaga(TM) for customers residing in the United States. Truvaga is a handheld non-invasive vagus nerve stimulator that utilizes proven technology to quickly and gently activate the vagus nerve. Stress affects every aspect of ives including sleep, memory, learning, weight, fitness and more. Truvaga offers a drug-free, simple, and convenient way to help reduce stress with just 2-minute sessions, day and night; no apps, batteries, chargers or phones are required.お知らせ • Nov 04electroCore, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022electroCore, Inc. provided revenue guidance for the fourth quarter of 2022. For the fourth quarter of 2022, the company expects net revenue to be between $2.2 million and $2.3 million.お知らせ • Oct 28electroCore, Inc. to Report Q3, 2022 Results on Nov 03, 2022electroCore, Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2022お知らせ • Oct 16electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022electroCore, Inc. provided revenue guidance for the third quarter of 2022. The Company anticipates reporting third quarter 2022 revenue of approximately $1,976,000. This represents approximately 33% growth over the third quarter 2021 revenue of $1,487,000.お知らせ • Sep 21electroCore, Inc., Annual General Meeting, Dec 02, 2022electroCore, Inc., Annual General Meeting, Dec 02, 2022.お知らせ • Sep 08electroCore, Inc. Announces Publication of a Peer Reviewed Manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use DisorderelectroCore, Inc. announced the publication of a peer reviewed manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder: A Double-Blind, Randomized, Sham-Controlled Pilot Study in the journal, Brain Stimulation. The study, conducted with the support of Emory and Georgia Tech University, was sponsored by a grant from the National Institute on Drug Addiction (NIDA), part of the National Institutes of Health (NIH), through NIH Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative. Substance use is an escalating crisis in the United States, with opioid-related drug overdose deaths rising above 100,000 in 2021. The standard of care for treating opioid use disorder (OUD) is medication for opioid use disorder (MOUD), including opioid receptor agonists and antagonists. Yet, the barriers to care are high with only 11% of patients who have OUD receiving the MOUD they need. Additionally, OUD relapse is common amongst patients. As many as 70% of patients with OUD return to use without medication and 46% of patients on methadone, an opioid agonist medication, will relapse. Treatment with the opioid antagonist naltrexone requires an extended period of detoxification before initiation, which can be associated with withdrawal symptoms. Relapse during this period may be associated with an even higher risk of relapse-related overdose and death. New treatments are therefore necessary for managing withdrawal in the treatment of OUD. This double-blind, randomized, sham-controlled study of 21 patients with OUD found that nVNS reduced both the psychological and physiological symptoms of acute opioid withdrawal. In particular, statistically significant reductions in opioid withdrawal symptoms (-1.9 ± 3.7 vs. 0.4 ± 1.0; p=0.047), distress (-17.5 ± 26.5 vs. 2.2 ± 5.9; p=0.004), and pain (-0.8 ± 2.4 vs. 0.9 ± 1.0; p=0.045) were observed over the course of a 2-hour protocol for the nVNS group, in comparison to the sham stimulation group. This was accompanied by a statistically significant decrease in heart rate during active nVNS compared to sham stimulation, across all stimulations (-5.5 ± 3.5 bpm vs. -1.4 ± 2.3 bpm; 0=0.035).お知らせ • Aug 06electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022electroCore, Inc. provided revenue guidance for the third quarter of 2022. FOr the quarter, the company expected net revenue to be approximately second quarter 2022 levels.お知らせ • Jul 29electroCore, Inc. to Report Q2, 2022 Results on Aug 04, 2022electroCore, Inc. announced that they will report Q2, 2022 results After-Market on Aug 04, 2022お知らせ • Jul 13electroCore, Inc. Provides Preliminary Unaudited Earnings Guidance for the Second Quarter of 2022electroCore, Inc. provided preliminary unaudited earnings guidance for the second quarter of 2022. For the quarter, the company expects revenue of more than $2,100,000. This represents at least an 11% increase over the first quarter 2022 revenue of $1,899,000 and approximately 65% growth over the second quarter 2021 revenue of $1,269,000.お知らせ • Jul 08Electrocore, Inc. Announces Study of Gammacore Sapphire™ for the Treatment of Post-Covid SyndromeelectroCore, Inc. announced Mayo Clinic is initiating an investigator-initiated study to assess the efficacy of gammaCore Sapphire non-invasive vagus nerve stimulation (nVNS) in patients with post-COVID syndrome. Post-COVID syndrome, also known as Long COVID, is a collection of symptoms that persist greater than 28 days after the initial onset of symptoms of SARS-CoV-2 (COVID) infection1,2. These symptoms, such as headache, brain fog, fatigue and gastric distress can bear a striking resemblance to the “central sensitization syndromes,” a group that includes fibromyalgia, chronic fatigue syndrome, and postural orthostatic tachycardia syndrome (POTS). Post-COVID syndrome is likely to occur in upwards of 10% of the population who has been infected with COVID, likely affecting hundreds of millions across the world. The study entitled “Outcomes of treatment with non-invasive vagal nerve stimulation (nVNS) in post-COVID syndrome: A Pilot Study,” is a randomized, single-center, controlled trial enrolling up to 20 subjects recruited from the Post-COVID Care Clinic at Mayo Clinic in Rochester, Minnesota. Endpoints of the study include a number of clinical questionnaires including the Post-COVID Functional Status Score, as well as an analysis of blood samples for certain chemokines, and positron emission tomography-computed tomography (PET-CT) of the brain to evaluate brain metabolism. gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore is self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania continua in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.お知らせ • Jun 24electroCore Announces Listing Transfer to the Nasdaq Capital MarketelectroCore, Inc. announced that it has received approval from the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. The Company's common stock will continue to be traded under the symbol "ECOR" and trading of its common stock will be unaffected by this transfer. This transfer will be effective as of the opening of business on June 23, 2022. As previously disclosed, on December 20, 2021, the Company received a letter from Nasdaq notifying the Company of its noncompliance with Nasdaq Listing Rule 5450(a)(1) (the “Rule”) by failing to maintain a minimum closing bid price for its common stock on the Nasdaq Global Select Market of at least $1.00 per share for 30 consecutive business days. The Company was given a period of 180 calendar days, or until June 20, 2022, to regain compliance with the minimum closing bid price requirement. In response to not achieving the minimum closing bid price, the Company submitted an application to transfer its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market. In connection with the transfer, Nasdaq granted the Company a second period of 180 calendar days, or until December 19, 2022, to regain compliance with the minimum closing bid price requirement for continued listing by achieving a closing bid price on Nasdaq of at least $1.00 per share for 10 consecutive business days. Nasdaq granted the additional 180-day compliance period as the Company continues to meet the listing requirements of the Nasdaq Capital Market with the exception of the minimum closing bid price requirement. The Company intends to continue to actively monitor its compliance with the minimum closing bid price requirement and, as appropriate, will consider available options to resolve any deficiencies and regain compliance.Recent Insider Transactions • Jun 17Co-Founder recently bought €53k worth of stockOn the 13th of June, Joseph Errico bought around 100k shares on-market at roughly €0.53 per share. This was the largest purchase by an insider in the last 3 months. This was Joseph's only on-market trade for the last 12 months.お知らせ • May 26Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain CenterselectroCore, Inc. announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator will be available for purchase through many of the more than 130 National Spine and Pain Centers affiliated locations across the United States for patients suffering from pain associated with different forms of primary headache.Reported Earnings • May 06First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.11 loss in 1Q 2021)First quarter 2022 results: US$0.079 loss per share. Revenue: US$1.90m (up 58% from 1Q 2021). Net loss: US$5.58m (loss widened 3.7% from 1Q 2021). Over the next year, revenue is forecast to grow 64%, compared to a 11% growth forecast for the industry in Germany.お知らせ • May 06electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2022electroCore, Inc. provided earnings guidance for the second quarter of 2022. For the period, the company expects net revenue to be at least $1.9 million.Board Change • Apr 27High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Director Tricia Wilber was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 22electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in NeurologyelectroCore, Inc. announced that Frontiers in Neurology has published results from an investigator-initiated trial, SAVIOR-1, a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore Sapphire™ in patients admitted to the hospital for treatment of COVID-19. The SAVIOR-1 trial was conducted by principal investigator Dr. Carlos Tornero, Head of the Department of Anesthesiology, Resuscitation and Pain Therapeutics of the Hospital Clínico Universitario de Valencia, Spain, between April 2020 and February 2021. The trial targeted patients over 18 years of age and enrolled 110 patients, randomly assigned, with 55 patients in each group. Of the 110 patients, 97 patients (47 in the nVNS treatment group, 50 in the control group) provided baseline demographic and medical history data and were the evaluable population. The study evaluated the safety and feasibility of nVNS when administered in addition to the then-standard of care in patients hospitalized with active SARS-CoV-2 infection compared with the standard of care alone. The study identified significant treatment differences for certain biomarkers of inflammation. Decreases from baseline in C-reaction protein (CRP) levels were significantly greater in the nVNS treatment group as compared to the control group throughout the five-day period combined (p=0.011) and on day 5 compared to the day 1 baseline period alone (p=0.015). On day 1, CRP levels were highly elevated for 90% of all subjects, but by days 3 and 5, the percentage of subjects with normal CRP levels improved markedly in the nVNS group with day 3 CRP levels at 17.9% vs. 52.2% in the control (p=0.010). Additionally, the nVNS group had a significantly greater decrease from baseline in procalcitonin level at day 5 (p=0.012) as compared to the control group. Increased levels of CRP, procalcitonin, and d-dimer have all been reported to be associated with more severe disease and the lower levels of these markers in the nVNS treated group may represent the initial impact of nVNS therapy to potentially improve the course of a patients’ COVID-19 symptoms. nVNS was well tolerated with no major device-related adverse events and the therapy was administered three times daily to most patients as outlined in the study protocol.お知らせ • Apr 13electroCore, Inc. Provides Unaudited Preliminary Revenue Guidance for the First Quarter of 2022electroCore, Inc. provided unaudited preliminary revenue guidance for the first quarter of 2022. The Company anticipates first quarter 2021 revenue from product sales will be approximately $1.9 million. This represents an approximately 27% increase over fourth quarter 2021 revenue of $1.5 million and approximately 60% growth over first quarter 2021 revenue of $1.2 million.Board Change • Apr 02High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Director Tricia Wilber was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 12Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.29 loss per share (up from US$0.60 loss in FY 2020). Revenue: US$5.45m (up 56% from FY 2020). Net loss: US$17.2m (loss narrowed 27% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 67%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.お知らせ • Mar 06electroCore, Inc. to Report Q4, 2021 Results on Mar 10, 2022electroCore, Inc. announced that they will report Q4, 2021 results After-Market on Mar 10, 2022お知らせ • Feb 02electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative IleuselectroCore, Inc. announced enrollment has been completed for the TRANSIT study of non-invasive vagal nerve stimulation (nVNS) to reduce ileus after colorectal surgery. This randomized, participant blinded, sham-controlled study is being sponsored by the United Kingdom’s National Institute for Health Research (NIHR). The 97-patient study is led by Dr. Stephen Chapman, Clinical Research Fellow in the University of Leeds School of Medicine. The study is conducted at St. James Hospital in Leeds, England and Bradford Royal Infirmary in Bradford, England. Ileus occurs in 10-20% of patients who have undergone elective colorectal surgery. Ileus is a distressing condition characterized by abdominal distension, persistent vomiting, and delayed return of bowel function after surgery. For patients, it prolongs the length of hospital stays and increases the risk of serious complications such as pneumonia and venous thromboembolic events. For healthcare systems, ileus increases per-patient costs by up to 71%, particularly those associated with nursing care, laboratory investigations, and medications. Clinical endpoints in the TRANSIT study include the number of postoperative days to first flatus, first stool, first oral intake, hospital discharge, and the GI-2 composite outcome, a common clinical measure of return of bowel function. The amount of daily oral morphine equivalent requirements, as well as a number of safety and feasibility outcomes to inform potential future clinical research and use, will also be assessed. Study results are expected later this year and will be presented at an appropriate medical congress.お知らせ • Jan 19electroCore, Inc. Provides Revenue Guidance for the Full Year of 2021electroCore, Inc. provided revenue guidance for the full year of 2021. The company anticipates full-year 2021 revenue will be approximately $5.5 million. This would represent an approximately 55% increase over full-year 2020 revenue of $3.5 million.お知らせ • Jan 13+ 1 more updateelectroCore, Inc. Announces Publication of Premium II Trial of Gammacore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of MigraineelectroCore, Inc. announced the publication of a peer-reviewed paper, entitled Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial in Cephalalgia, the official journal of the International Headache Society (IHS). The paper reports the results of a randomized, double-blind, sham-controlled trial conducted at twenty-seven sites across the United States. Originally designed and powered to randomize 400 patients, the study was closed early due to COVID-19 after enrolling 231 subjects. The results of the study showed a decrease in the number of monthly headache days of 4.6 vs. -3.0 for sham (p=0.05) with 44.87% of subjects in the gammaCore group having greater than a 50% reduction in the number of migraine days per month compared with 26.81% for the sham group (p=0.05). Quality of life, as measured by the HIT-6 (Headache Impact scale), improved by -4.9 points vs. -2.3 for sham (p<0.05). In the subpopulation of patients diagnosed with migraine with aura, the number of headache days decreased by 5.5 days in the nVNS group compared with 2.7 in the sham group (p=0<0.05), a therapeutic gain of >100% compared to sham. These findings are consistent with previous reports on the mechanisms of action that suggest nVNS may be particularly effective in patients with migraine with aura.Reported Earnings • Nov 06Third quarter 2021 earnings released: US$0.057 loss per share (vs US$0.10 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$1.49m (up 38% from 3Q 2020). Net loss: US$3.99m (loss narrowed 11% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.お知らせ • Sep 15electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania ContinuaelectroCore, Inc. announced that on September 10, 2021 the company received Section 510(k) clearance from the United States Food and Drug Administration (FDA) of the company’s submission to expand the label of gammaCore nVNS to include the treatment of Paroxysmal Hemicrania (PH) and Hemicrania Continua (HC) in adults. PH and HC are both rare forms of trigeminal autonomic cephalalgias (TAC), that are typically debilitating and difficult to treat. The most common type of TAC is cluster headache. gammaCore is also indicated for both the acute and preventative treatment of cluster headache, where it is considered a first-line treatment option. The label expansion was based on data collected from multiple clinical audits and case series/case reports that included patients with PH or HC. These included a total of 14 patients with PH and 19 patients with HC. 79% of the patients experienced clinically meaningful benefits from gammaCore for each indication, including decreases in the severity of persistent pain and/or reductions in the frequency, severity, and/or duration of exacerbations or attacks. Many subjects reported more than one clinical benefit. There were no serious or unexpected adverse events reported.Reported Earnings • Aug 09Second quarter 2021 earnings released: US$0.06 loss per share (vs US$0.13 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$1.27m (up 69% from 2Q 2020). Net loss: US$2.89m (loss narrowed 39% from 2Q 2020).お知らせ • Jul 15electroCore, Inc. Announces Revenue Guidance for the Second Quarter of 2021electroCore, Inc. announced revenue guidance for the second quarter of 2021. The company anticipates that second quarter 2021 revenue will be approximately $1.3 million.お知らせ • Jul 01electroCore, Inc. has completed a Follow-on Equity Offering in the amount of $18 million.electroCore, Inc. has completed a Follow-on Equity Offering in the amount of $18 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 18,000,000 Price\Range: $1 Discount Per Security: $0.08お知らせ • Jun 03electroCore, Inc. Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’S Disease PatientselectroCore, Inc. announced the publication of a peer-reviewed paper, entitled “Non-Invasive Vagus Nerve Stimulation Improves Clinical and Molecular Biomarkers of Parkinson’s Disease in Patients with Freezing of Gait” in the journal NPJ Parkinson’s Disease. The paper reports the results of a randomized, double-blind, sham-controlled crossover trial conducted at the Institute of Neurosciences in Kolkata, India in collaboration with the Faculty of Medical Sciences at Newcastle University in England using gammaCore SapphireTM. The study was funded by the Institute of Neurosciences, Kolkata, India. Neurological disorders are now the leading source of disability in the world, and Parkinson’s disease is the fastest-growing of these disorders. As populations age and life expectancy increases, the number of individuals with Parkinson’s disease and the duration of the disease will increase, leading to more patients with advanced Parkinson’s disease. To address this burden, primary prevention strategies based on the underlying causes of Parkinson’s disease and more effective symptomatic treatments are needed. The study, which enrolled thirty-six subjects, was undertaken to explore the safety, feasibility and efficacy of self-administered non-invasive vagus nerve stimulation (nVNS) in the treatment of gait and other motor symptoms in Parkinson’s disease (PD) patients. In a subgroup of study patients, levels of selected neurotrophins, markers of inflammation and oxidative stress were measured in blood before and after nVNS. Vagus Nerve Stimulation (VNS) has been found to be beneficial in improving locomotion in a rat model of PD,3 and two independent preliminary studies found improvement in gait in patients with PD after a single application of cervical nVNS. The study provides preliminary evidence supporting the safety and efficacy of nVNS in treating motor and non-motor symptoms of PD. Patients were satisfied with the treatment and the majority were able to self-administer nVNS. Adverse events were infrequent, non-serious, and similar across both Active and Sham groups. Significant increases in velocity (p=0.003), step length (p=0.007), and a reduction in stance time (p=0.001) were seen in the nVNS treated group compared to sham stimulation, indicating that PD patients were walking not only with a faster pace but also with improved rhythm. Other gait parameters also showed significant improvement from baseline in all five domains, specifically after nVNS treatment, suggesting that nVNS may result in an overall improvement in the quality of gait in PD patients. Treatment with nVNS significantly reduced TNF-a levels (p<0.05) and increased concentrations of reduced glutathione (p<0.05), which are both markers of inflammation in PD patients. Brain Derived Neurotrophic Growth Factors, which are reduced in PD, were significantly increased by nVNS (p<0.05) suggesting a possible disease modifying effect.お知らせ • May 25electroCore, Inc. Develops Non-Drug and Non-Invasive Alternative to Pharmaceuticals That Safely and Effectively Stimulates the Vagus Nerve to Communicate with the Brain and Help Optimize the Body’s Own Ability to Control Problems Impacting Its HealthelectroCore, Inc. developed a non-drug and non-invasive alternative to pharmaceuticals that safely and effectively stimulates the vagus nerve to communicate with the brain and help optimize the body’s own ability to control problems impacting its health. While vagus nerve stimulation (VNS) has been available for decades, electroCore has transformed the industry with non-invasive vagus nerve stimulation (nVNS) therapy which taps into the power and potential of the vagus nerve via a portable device. Implanted Vagus Nerve Stimulation (iVNS), which involves the surgical implantation of a device, was one of the first major breakthroughs highlighting how electrical stimulation could be used to treat conditions such as depression, epilepsy, infectious disease, and heart disease. In 2008, electroCore joined this medical exploration and two years later created a non-invasive way of delivering VNS therapy. Between 2011 and 2017, nVNS received CE Marks, which means it fulfilled the requirements of relevant European product directives in addition to performance and safety standards, for the treatment of multiple conditions in neurology, psychiatry, and gastroenterology. In 2017, electroCore’s nVNS received its first FDA clearance for the acute treatment of episodic cluster headache. Since then, electroCore’s game changing nVNS therapy received four additional FDA clearances as well as growing acknowledgement from health care providers and patients as a front-line, non-drug option for the treatment and prevention of migraine and cluster headache. The creation of a safe, patient-controlled way of activating the vagus nerve has opened the door for the research and clinical community to study the vagus nerve’s potential to treat several conditions more easily and safely. At the forefront of medicine, electroCore and other organizations are expanding research on the vagus nerve with clinical studies of nVNS’s effectiveness on conditions including COVID-19, post-traumatic headache, traumatic brain injury, post-traumatic stress disorder, Parkinson’s disease, epilepsy, stroke, sub-arachnoid hemorrhage and addiction as well as a number of gastrointestinal and inflammatory conditions.Reported Earnings • May 09First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.27 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$1.20m (up 64% from 1Q 2020). Net loss: US$5.38m (loss narrowed 32% from 1Q 2020).お知らせ • May 07electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2021electroCore, Inc. provided earnings guidance for the second quarter of 2021. For the second quarter of 2021, the company expects net revenue to exceed $1.2 million and net cash usage, exclusive of financing activities, to approximate First Quarter 2021 levels.お知らせ • Apr 27electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related DisorderselectroCore, Inc. announced that Johns Hopkins University School of Medicine is starting an investigator-initiated trial of non-invasive vagus nerve stimulation (nVNS) using the Company’s proprietary gammaCore device to treat symptomatic exacerbation of nausea in patients with gastroparesis and related disorders (NCT04857281). Many gastrointestinal disorders can cause nausea and vomiting, of which the most well-known is gastroparesis, a digestive disorder in which the stomach empties slowly. The symptoms of gastroparesis can range from mild to severe, requiring prolonged hospitalizations and interventions, and causing life-threatening complications which can significantly affect the quality of life in affected individuals. It is estimated that close to 6 million Americans suffer from gastroparesis which is more common in women than men.2 The economic impact of gastroparesis can be substantial, with studies reporting 11% of patients disabled due to their gastroparesis symptoms, while another 28.5% reported a loss of yearly income. Nausea without slow gastric emptying may be even more common and has been referred to by many names, including chronic unexplained nausea and vomiting (CUNV), gastroparesis-like syndrome (GLS), functional vomiting, and vomiting of unexplained etiology (VUE). Many of these patients can be classified as having functional dyspepsia (FD) which is a disorder that may affect 10% of the US population.お知らせ • Apr 14ElectroCore, Inc. Provides Revenue Guidance for the First Quarter of 2020electroCore, Inc. provided revenue guidance for the first quarter of 2020. For the quarter, the company anticipates that first quarter 2021 revenue will be more than $1.1 million, representing greater than 50% growth over first quarter 2020 revenue of $0.7 million and greater than 20% growth over fourth quarter 2020 revenue of $0.9 million.Reported Earnings • Mar 16Full year 2020 earnings released: US$0.60 loss per share (vs US$1.54 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$3.50m (up 46% from FY 2019). Net loss: US$23.5m (loss narrowed 48% from FY 2019).お知らせ • Mar 05electroCore, Inc. to Report Q4, 2020 Results on Mar 11, 2021electroCore, Inc. announced that they will report Q4, 2020 results After-Market on Mar 11, 2021お知らせ • Mar 01electroCore, Inc. Announces Exclusive Distribution Agreement with Medistar2 PTY Limited Following Regulatory Approval in AustraliaelectroCore, Inc. announced that it has entered into an agreement with Medistar2 PTY Limited (“Medistar”) whereby Medistar will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Australia, supplying therapy to patients suffering with primary headache disorders. The announcement follows the granting of regulatory approval from the Australian Therapeutic Goods Administration (TGA) for the promotion and sale of the gammaCore Sapphire family of products. The initial term of the agreement is three years and contains customary terms and conditions, including minimum purchase commitments. Medistar will be officially launching gammaCore Sapphire at the 2021 ANZHS Headache Annual Scientific Meeting, which will be held on March 13-14.お知らせ • Feb 25Non-Invasive Vagus Nerve Stimulation (Nvns) Enters New Stage of Covid-19 Research of electrocore, IncelectroCore, Inc. announced the completion of patient enrollment in SAVIOR-1, or “Prospective, Randomized, Controlled Study to Evaluate the Effect of Non-Invasive Electrical Vagus Nerve Stimulation on Respiratory Symptoms due to COVID-19.” This study was supported in part by electroCore. Closing enrollment for this study is an important step to better understanding the clinical benefit of non-invasive vagus nerve stimulation (nVNS) and how it can help patients suffering from COVID-19 respiratory distress. gammaCore SapphireTM CV (nVNS) received Emergency Use Authorization from the FDA in July of 2020 to treat patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow.収支内訳electroCore の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:43E0 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Jun 2637-1543331 Mar 2635-1542331 Dec 2532-1438330 Sep 2530-1436330 Jun 2528-1334231 Mar 2526-1232331 Dec 2425-1231230 Sep 2423-1330330 Jun 2421-1429331 Mar 2419-1628431 Dec 2316-1927530 Sep 2313-2126630 Jun 2311-2225631 Mar 239-2225631 Dec 229-2224630 Sep 228-2124530 Jun 227-2023331 Mar 226-1722331 Dec 215-1722330 Sep 215-1921330 Jun 214-1921331 Mar 214-2121331 Dec 203-2422430 Sep 203-2624530 Jun 203-3227631 Mar 203-3931831 Dec 192-45351030 Sep 192-52411230 Jun 192-55441231 Mar 191-49471431 Dec 181-35431230 Sep 181-19361030 Jun 181-6291031 Mar 181622831 Dec 171018831 Dec 160-1678質の高い収益: 43E0は現在利益が出ていません。利益率の向上: 43E0は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 43E0は利益を出していないが、過去 5 年間で年間9%の割合で損失を削減してきた。成長の加速: 43E0の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 43E0は利益が出ていないため、過去 1 年間の収益成長をMedical Equipment業界 ( 11.7% ) と比較することは困難です。株主資本利益率高いROE: 43E0の負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/09 22:50終値2026/08/07 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋electroCore, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Fozia AhmedBrookline Capital MarketsTyler BussianBrookline Capital MarketsBrian Kemp DolliverBrookline Capital Markets7 その他のアナリストを表示
Reported Earnings • 21hSecond quarter 2026 earnings released: US$0.33 loss per share (vs US$0.44 loss in 2Q 2025)Second quarter 2026 results: US$0.33 loss per share (improved from US$0.44 loss in 2Q 2025). Revenue: US$9.45m (up 28% from 2Q 2025). Net loss: US$3.06m (loss narrowed 17% from 2Q 2025). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Jul 30electroCore, Inc. to Report Q2, 2026 Results on Aug 06, 2026electroCore, Inc. announced that they will report Q2, 2026 results After-Market on Aug 06, 2026
お知らせ • Apr 29electroCore, Inc. to Report Q1, 2026 Results on May 06, 2026electroCore, Inc. announced that they will report Q1, 2026 results After-Market on May 06, 2026
お知らせ • Mar 09electroCore, Inc. to Report Q4, 2025 Results on Mar 19, 2026electroCore, Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026
お知らせ • Oct 23electroCore, Inc. to Report Q3, 2025 Results on Nov 05, 2025electroCore, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2025
お知らせ • Jul 23electroCore, Inc. to Report Q2, 2025 Results on Aug 06, 2025electroCore, Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025
Reported Earnings • 21hSecond quarter 2026 earnings released: US$0.33 loss per share (vs US$0.44 loss in 2Q 2025)Second quarter 2026 results: US$0.33 loss per share (improved from US$0.44 loss in 2Q 2025). Revenue: US$9.45m (up 28% from 2Q 2025). Net loss: US$3.06m (loss narrowed 17% from 2Q 2025). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany.
お知らせ • 22hElectrocore, Inc. Increases Earnings Guidance for the Full Year 2026electroCore, Inc. increased earnings guidance for the full year 2026. For the period, the company expects revenue guidance to greater than 30% annual growth over full-year 2025.
Breakeven Date Change • Aug 07The 5 analysts covering electroCore previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 54% per year to 2027. The company is expected to make a profit of US$4.62m in 2028. Average annual earnings growth of 88% is required to achieve expected profit on schedule.
お知らせ • Jul 30electroCore, Inc. to Report Q2, 2026 Results on Aug 06, 2026electroCore, Inc. announced that they will report Q2, 2026 results After-Market on Aug 06, 2026
お知らせ • Jul 21electroCore, Inc., Annual General Meeting, Sep 08, 2026electroCore, Inc., Annual General Meeting, Sep 08, 2026.
Recent Insider Transactions • May 29Founder & Independent Chairman recently bought €52k worth of stockOn the 21st of May, Thomas Errico bought around 10k shares on-market at roughly €5.17 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Thomas has been a buyer over the last 12 months, purchasing a net total of €109k worth in shares.
New Risk • May 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.9m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-US$5.7m). Minor Risks Significant insider selling over the past 3 months (€82k sold). Market cap is less than US$100m (€63.6m market cap, or US$73.9m).
お知らせ • May 15electroCore, Inc. Announces Publication in JAMA Highlighting Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in FibromyalgiaelectroCore, Inc. announced the publication of new clinical findings in JAMA Network Open titled, Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial. The study evaluated the use of a modified Quell device, an FDA-authorized nonpharmacological wearable stimulation device, when added to outpatient physical therapy (“PT”) for people with fibromyalgia. The trial enrolled 384 participants [that completed baseline data collection], including 191 individuals in the PT-Quell group and 193 individuals in the PT-only group. At day 60, reduction in movement-evoked pain was significantly greater in the PT-Quell group compared with the PT-only group, (between-group difference, -1.2 points [95% CI, -1.6 to -0.7]; P<.001), and statistically significant improvements favoring the PT-Quell group were also observed across several other secondary measures, including resting pain, pain interference, movement-evoked fatigue, resting fatigue, and fibromyalgia impact (FIQR) during the randomized phase. The benefits of Quell were observed within 30 days and were sustained for up to six months. Among respondents, 81% reported finding Quell helpful, and 55% continued to use Quell daily.
お知らせ • Apr 29electroCore, Inc. to Report Q1, 2026 Results on May 06, 2026electroCore, Inc. announced that they will report Q1, 2026 results After-Market on May 06, 2026
お知らせ • Apr 09Electrocore Inc Announces First Patient Enrollment in Investigator-Led Study of Gammacore nVNS for PTSDElectroCore, Inc. announced the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society. The study is designed to evaluate the safety and effectiveness of electroCore’s gammaCore non-invasive vagus nerve stimulation (nVNS) device as an adjunctive treatment for symptoms associated with PTSD. The study is expected to enroll up to 40 adult participants and will assess outcomes over a 12-week treatment period. The primary safety endpoint is the incidence of treatment-related serious adverse events, and the primary efficacy endpoint is the change from baseline in the Clinician-Administered PTSD Scale (CAPS-5) total score at 12 weeks. Secondary endpoints include changes in PTSD Checklist (PCL-5) scores and Clinical Global Impression (CGI) ratings. The study is sponsored by the Vagus Nerve Society, with electroCore providing an educational grant and gammaCore devices. The study is anticipated to run for approximately 10 months and is intended to generate preliminary safety and effectiveness data to inform future research in neuropsychiatric applications of nVNS.
お知らせ • Apr 01ElectroCore Inc Announces Publication Highlighting Benefits Of Non-Invasive Vagus Nerve Stimulation In Patients With Mild Traumatic Brain Injury And PTSDElectroCore, Inc. announced the publication of new clinical findings in Frontiers in Neuroscience titled “Adjunctive non-invasive vagus nerve stimulation for chronic mild traumatic brain injury with comorbid post-traumatic stress disorder: a post-hoc analysis” by Drs. Michael Ament, Peter Staats, Norianne Theresa Ingram, and Emily Leonard, demonstrating the potential benefits of adjunctive non-invasive vagus nerve stimulation (nVNS) in patients with chronic mild traumatic brain injury (mTBI) and comorbid post-traumatic stress disorder (PTSD). The publication reports results from a post-hoc analysis of 35 patients with chronic mTBI and PTSD. The analysis showed that adjunctive nVNS significantly reduced overall symptom burden, with observed improvements across cognitive, affective, and somatic domains. The study population represented a high-symptom-burden cohort commonly associated with persistent and difficult-to-treat neurobehavioral symptoms. The full article can be accessed here: Frontiers: nVNS for mTBI and PTSD. These findings contribute to the growing body of evidence supporting the therapeutic potential of nVNS in patients with chronic mTBI and comorbid PTSD.
お知らせ • Mar 20+ 2 more updateselectroCore, Inc. Provides Revenue Guidance for the Full Year of 2026electroCore, Inc. provided revenue guidance for the full year of 2026. For the period, the company expects revenue of approximately 30% annual revenue growth over 2025.
お知らせ • Mar 09electroCore, Inc. to Report Q4, 2025 Results on Mar 19, 2026electroCore, Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026
お知らせ • Jan 21electroCore, Inc. Provides Earnings Guidance for the Fourth Quarter and Year Ended December 31, 2025electroCore, Inc. provided earnings guidance for the fourth quarter and year ended December 31, 2025. The company anticipated reporting fourth quarter 2025 revenue is anticipated to be approximately $9.0 - $9.2 million, which would represent approximately 30% growth over fourth quarter of 2024. The company anticipated reporting record full year 2025 revenue of approximately $31.8 - $32.0 million. This would represent approximately 26% growth over full-year 2024 revenue of $25.2 million.
お知らせ • Oct 23electroCore, Inc. to Report Q3, 2025 Results on Nov 05, 2025electroCore, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2025
お知らせ • Oct 18electroCore, Inc. announced that it has received $1.856 million in fundingOn October 17, 2025, electroCore, Inc closed the transaction. the transaction included participation from 3 Investors.
お知らせ • Oct 02electroCore, Inc. Announces the Publication of A Peer-Reviewed Study in Frontiers in Neurology Demonstrating the Effectiveness of gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) in Reducing Persistent Post-Concussion SymptomselectroCore, Inc. announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). The article, entitled "Non-invasive vagus nerve stimulating is associated with the reduction in persistent post-concussion symptoms: an observational study," found that adjunctive use of gammaCore with standard care was associated with significant and clinically meaningful improvements across multiple domains of the Neurobehavioral Symptom Inventory (NSI). The study included 102 patients with persistent symptoms following mTBI. Patients experienced significant reductions in 16 of 22 symptom categories, including post-traumatic headache, dizziness, difficulty concentrating, and depression. Approximately 34% of patients reported meaningful improvement in at least half of their persistent symptoms. Importantly, improvements were observed both in patients treated within three months of injury and in those whose symptoms had persisted for over a year, suggesting that nVNS may be beneficial regardless of time since injury.
お知らせ • Sep 30electroCore Announces Reimbursement Approval for gammaCore by RIZIV/INAMI in BelgiumelectroCore, Inc. announced that gammaCore Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV /INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clinical evidence supporting the therapy's efficacy and cost-effectiveness and ensures broader access for Belgian patients. This achievement was made possible through the leadership and commitment of Silvert Medical, electroCore's distribution partner in Belgium. Silvert Medical leveraged their local expertise and strong provider relationships, playing a key role in securing reimbursement. Silvert Medical remains a vital partner in supporting the rollout of gammaCore in Belgium and is committed to extending access to gammaCore in neighboring countries.
お知らせ • Sep 05electroCore, Inc. Announces Management ChangeselectroCore, Inc. announced the departure of Peter Cuneo from the Board of Directors and that Thomas J. Errico, MD, has been elected to succeed Mr. Cuneo as Chairman of the Board, effective September 2, 2025. Mr. Cuneo will continue as a strategic advisor to the Company.
お知らせ • Sep 04electroCore, Inc. Announces Board ChangeselectroCore, Inc. announced that Elena Bonfiglioli, an accomplished healthcare executive, has been appointed to electroCore’s Board of Directors, effective September 2, 2025. Ms. Bonfiglioli’s appointment follows the retirement from the Board of Peter Cuneo. Ms. Bonfiglioli has been working in the health sector for more than two decades. She currently serves as Microsoft’s Global Business Leader for Healthcare, Pharma Life Sciences, and the International clinical applications’ solutions, responsible for go-to-market, commercial, and partnerships, enabling artificial intelligence (“AI”) transformation initiatives in health providers, payors and Life Sciences’ organizations globally. Since 2023, Ms. Bonfiglioli has been a Member of the Drug Information Association (“DIA”) for Europe, Middle East & Africa Regional Advisory Council, and serves as a board member of several startups in Europe and the Middle East and as advisor for biopharma organizations. Ms. Bonfiglioli was selected twice as one of the top 50 AI Innovators by Intelligent Health and was one of the founding members of the Holomedicine Association; and Vice Chair of the DIGITALEUROPE Executive Council for Healthcare since its creation in 2021. Ms. Bonfiglioli was a champion for secondary use of data to enhance research and activate the power of data to save lives. She recently joined the Board of The Women Health Initiative, a community powered by Kearney. She is active in the field of longevity and champions the shift to health enhanced by data and AI.
お知らせ • Aug 12electroCore, Inc. Announces Appointment of Kelly Benning as Senior Vice President of Truvaga, Effective July 21, 2025electroCore, Inc. announced that Kelly Benning has been hired as the Senior Vice President of Truvaga, effective July 21, 2025.Ms. Benning, who brings almost three decades of leadership experience across digital health, AI-enabled technologies, and consumer wellness, will lead electroCore’s consumer wellness division. Ms. Benning has successfully brought pioneering digital health products to market, including the first and only FDA-cleared watch to monitor blood pressure, delivering breakthrough solutions and expertly navigating the commercialization process. Her interest in AI and machine-learning has led her to drive continual innovation and consistent market adoption of technology at the intersection of healthcare, data, and consumer experience.Throughout her career, Ms. Benning has worked with a multitude of consumer retailers, payors, providers, and healthcare enterprises to bring clinically impactful and commercially successful products to market. She currently serves as Senior Vice President of Truvaga, electroCore’s digital wellness platform, where she leads strategy, operations, and growth. Prior to joining electroCore, Ms. Benning held executive leadership roles including President at LiveMetric, Vice President of Sales at IBM Watson Health, and senior roles at CipherHealth, Savonix, Healthgrades, and National Jewish Health. Ms. Benning holds a Bachelor of Arts in Kinesiology and Exercise Science from the University of Colorado Boulder.
お知らせ • Aug 09electroCore, Inc Provides Earnings Guidance for the Full Year 2025electroCore, Inc. provided earnings guidance for the full year 2025. for the year, the company expects total revenue to be approximately $30.0 million and net cash usage for the remainder of the year to be between approximately $3.9 and $4.4 million.
お知らせ • Aug 06electroCore, Inc. Appoints James C. Theofilos to its Board of Directors, Effective August 1, 2025electroCore, Inc. announced that James C. Theofilos has been appointed to the Board of Directors, effective August 1, 2025. Mr. Theofilos has been a Senior Finance Manager within the Azure and artificial intelligence division of Microsoft Corporation since October 2023. In this role, Mr. Theofilos is the Go-to-Market Finance Lead across Microsoft’s AI Apps & Agents team, which includes all of Microsoft’s AI models, GitHub Copilot, Copilot Studio, and other products that aim to deliver the full value of AI & Agents. Previously, Mr. Theofilos held various finance positions at Microsoft including his position as the Finance Lead for Microsoft’s Global Healthcare & Life Sciences Sales team, which included exposure to the Health Providers, Payors, Pharma and Med Tech industry verticals. Prior to that, Mr. Theofilos consulted as a Group Project Manager at VICI Properties Inc. Mr. Theofilos holds an M.S. in Finance and a B.S.B.A. in Finance from Washington University in Saint Louis.
お知らせ • Jul 23electroCore, Inc. to Report Q2, 2025 Results on Aug 06, 2025electroCore, Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025
お知らせ • Jul 18electroCore, Inc., Annual General Meeting, Sep 02, 2025electroCore, Inc., Annual General Meeting, Sep 02, 2025.
お知らせ • May 16Happy Holstein Management, LLC Provides Information to the electroCore, Inc.On May 14, 2025, Happy Holstein Management, LLC announced that they are evaluating the feasibility of a change in the present board of directors or management of electroCore, Inc, including plans or proposals to nominate one or more director candidates, to amend the Company's charter and bylaws to remove the classified board, and other proposals to improve the corporate governance and transparency at the Company. Consistent with their investment purpose and subject to any applicable confidentiality obligations, one or more Happy Holstein Management, LLC or their representatives may engage in communications regarding the Company with other persons, including, without limitation, one or more shareholders of the Company, one or more officers of the Company and/or one or more members of the Board of Directors of the Company.
お知らせ • May 08electroCore, Inc. Provides Preliminary Revenue Guidance for Year Ending December 2025electroCore, Inc. provided preliminary revenue guidance for year ending December 2025. For the year, the company expects total revenue to be approximately $30.0 million.
お知らせ • Apr 30electroCore, Inc. to Report Q1, 2025 Results on May 07, 2025electroCore, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025
お知らせ • Mar 06electroCore, Inc. to Report Q4, 2024 Results on Mar 12, 2025electroCore, Inc. announced that they will report Q4, 2024 results After-Market on Mar 12, 2025
お知らせ • Mar 01electroCore, Inc. Announces Resignation of Charles S. Theofilos as A Class III Director of the Board, as A Member of the Compensation Committee of the Board, and as A Member of the Nominating and Governance CommitOn February 24, 2025, Charles S. Theofilos, M.D., a member of the Board of Directors of electroCore, Inc. resigned as a Class III director of the Board, as a member of the Compensation Committee of the Board, and as a member of the Nominating and Governance Committee of the Board, in each case effective immediately. In connection with Dr. Theofilos’ resignation, on February 28, 2025, the Board decreased the size of the Board from eight to seven members, effective immediately.
お知らせ • Jan 25electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Dec 18electroCore, Inc. (NasdaqCM:ECOR) entered into an agreement and plan of merger to acquire NeuroMetrix, Inc. (NasdaqCM:NURO).electroCore, Inc. (NasdaqCM:ECOR) entered into an agreement and plan of merger to acquire NeuroMetrix, Inc. (NasdaqCM:NURO) on December 17, 2024. At the effective time of the Merger (the “Effective Time”), each share of common stock, par value $0.0001 per share, of the Company (the “Company Common Stock”) outstanding immediately prior to the Effective Time, shall be cancelled and cease to exist and shall be converted into the right to receive (i) an amount in cash (the “Per Share Cash Consideration’) equal to a pro rata share of the Company’s balance of Net Cash (as determined pursuant to the Merger Agreement) at the Effective Time, after deduction of certain pro rata payments that will be due in accordance with the MRIP (as defined below), without interest and (ii) one contingent value right (a “CVR"), which shall represent the right to receive the Contingent Payments (as defined below) subject to the terms and conditions set forth in the CVR Agreement. Under the terms of the merger agreement, a subsidiary of electroCore will merge with NeuroMetrix and NeuroMetrix will become a wholly owned subsidiary of electroCore. Upon termination of the Merger Agreement under specified circumstances, the NeuroMetrix will be required to pay electroCore a termination fee of $500,000. Consummation of the Merger is subject to customary closing conditions, including, without limitation, the absence of certain legal impediments, the approval by the holders of a majority of the outstanding shares of NeuroMetrix Common Stock entitled to vote on the Merger, the determination of Net Cash pursuant to the Merger Agreement, and the filing by the NeuroMetrix of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close late in the first quarter of 2025. Ira Kotel and Ilan Katz of Dentons US LLP acted as legal advisors to electroCore. Megan Gates of Covington& Burling LLP acted as legal advisor to NeuroMetrix in the transaction.
お知らせ • Nov 30electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Oct 23electroCore, Inc. to Report Q3, 2024 Results on Nov 13, 2024electroCore, Inc. announced that they will report Q3, 2024 results After-Market on Nov 13, 2024
お知らせ • Jul 31electroCore, Inc. to Report Q2, 2024 Results on Aug 07, 2024electroCore, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024
お知らせ • Jul 18electroCore, Inc., Annual General Meeting, Sep 03, 2024electroCore, Inc., Annual General Meeting, Sep 03, 2024.
お知らせ • Jun 26electroCore Announces the Commercial Launch of TAC-STIM™?electroCore, Inc. announced the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM™?, a non-invasive vagus nerve stimulator (nVNS) designed in partnership with the US military to enhance human performance exclusively for active-duty military use. TAC-STIM is a cutting-edge device that can accelerate learning and improve mood and cognitive performance. TAC-STim is a portable, easy-to-use tool that leverages electroCore's patented technology to deliver precise and effective vagus nerve stimulation, helping war fighters and operators learn new tasks, increase readiness and mitigate fatigue across a range of high-pressure operational environments. TAC-STIM was originally developed in close collaboration with the 711th Human Performance Wing at the Air Force Research Laboratory (AFRL), Wright-Patterson AFB, OH, as part of the United States Department of Defense Biotech Optimized for Operational Solutions and tactics (BOOST) program. Independent testing by AFRL and Air Force Special Operations Command consistently demonstrated its capabilities across a range of operational settings. electroCore continues to participate in collaborative research to further enhance TAC-STIMs operational utility and showcase how TAC-STIM can enhance performance, reduce fatigue, and accelerate training without adverse effects. Key benefits of TAC-STIM include: Improve performance and combat fatigue for 12-24 hours under extreme conditions; 20-35% faster learning of complex material; Enhance ability to multi-task; Significantly decreased fatigue and increased focus.
お知らせ • Jun 08+ 1 more updateelectroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million.electroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million. Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 225,000 Price\Range: $6.429 Transaction Features: Registered Direct Offering
お知らせ • Jun 05+ 1 more updateelectroCore, Inc. announced a financing transactionelectroCore, Inc. announced a private placement of 1,208,310 common shares and warrants on June 3, 2024. The warrants can be exercisable into an aggregate of 604,150 shares of common stock. The transaction is expected to close on June 5, 2024.
お知らせ • May 06electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and ComplianceelectroCore, Inc. announced that on May 1, 2024, Donald Melnikoff joined electroCore as the Company’s SVP, Engineering, Regulatory, and Compliance; the Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Melnikoff in connection with the commencement of his employment.
お知らせ • May 03electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024electroCore, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024
お知らせ • Apr 30electroCore, Inc. Announces Results of Truvaga Plus Consumer StudyelectroCore, Inc. announced the results of its most recent Truvaga Plus consumer study conducted earlier this year. Based on a 30-day in-home use test by an independent third-party research firm, Truvaga Plus helped its users improve sleep, focus, stress, energy, and mood. 39 participants were instructed to use the Truvaga Plus product at home twice a day for 30 days to assess the product's benefits, efficacy, and overall user experience. Self-assessment evaluations were reported after 7 and 30 days. After 30 days, users reported the following: 82% felt calmer; 82% felt mentally healthier; 77% felt more alert; 77% felt more relaxed; 74% felt they sleep better; 74% felt their mood improved; and 67% had more energy. Of those that felt they slept better, 72% reported they received between 30 minutes to 2+ hours or more sleep each night. After the study completed, 87% of users said they were likely to continue to use Truvaga Plus for ongoing overall wellness benefits.
お知らせ • Apr 10electroCore, Inc. Announces the Launch of Truvaga Plus® for General WellnesselectroCore, Inc. announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024. Key features of Truvaga Plus include: Mobile App Connectivity: Empowering users to control sessions, plan schedules, and track progress conveniently through integrated mobile application. Unlimited Sessions: Providing users with the flexibility for prolonged usage and extended benefits, ensuring continuous support for achieving optimal wellness. Rechargeable: Enhancing sustainability and user convenience, Truvaga Plus features a rechargeable design for uninterrupted usage. Compact Design: Sleeker, smaller, and more portable, the new design of Truvaga Plus ensures enhanced user comfort and convenience.
お知らせ • Mar 06electroCore, Inc. to Report Q4, 2023 Results on Mar 13, 2024electroCore, Inc. announced that they will report Q4, 2023 results After-Market on Mar 13, 2024
お知らせ • Dec 15electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the BoardOn December 8, 2023, the board of directors (the “ Board”) of electroCore, Inc. (the “ Company”) appointed Charles S. Theofilos, M.D., as a new Class III member of the Board. The term of each Class III director lasts until the Company’s 2024 annual meeting of stockholders. In connection with the appointment of Dr. Theofilos to the Board, the size of the Board was increased by resolution of the Board from seven members to eight members on December 8, 2023. Dr. Theofilos is a retired neurosurgeon who founded The Spine Center in Palm Beach Gardens, FL in 1996. He also founded and serves as President of Theo Concepts, LLC and Founder of The Theo Group, a family office. Previously, he served as Co-Director of the Neuroscience Center, Chairman of Neurosurgery, and Chairman of Cranial and Spinal Surgery, at JFK Medical Center in Atlantis, Florida, Director of Spine Surgery at Jupiter Medical Center, and Chairman of Neurosurgery at Palm Beach Gardens Medical Center. Dr. Theofilos has been a founder, director and/or investor in a number of early-stage medical device and healthcare companies, including K2Medical, SpineCore LLC and electroCore, LLC, a predecessor of the Company. Dr. Theofilos received an M.D. from Emory University School of Medicine, a B.A. in biology from Emory University, and a GMP (General Management Program) from The Wharton School of The University of Pennsylvania.
お知らせ • Oct 26Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation (Nvns) for Treatment of Symptoms of GastroparesiselectroCore, Inc. announced top line data from an abstract being presented as an oral podium presentation at the 2023 American College of Gastroenterology Annual Meeting held in Vancouver, Canada from October 23- 25, 2023 regarding the potential for nVNS to decrease the use of acute rescue medications for exacerbations of nausea due to Gastroparesis (GP) or Functional Dyspepsia (FD). Many gastrointestinal disorders can cause nausea and vomiting, of which the most well-known is gastroparesis, a digestive disorder in which the stomach empties slowly. The symptoms of gastroparesis can range from mild to severe, requiring prolonged hospitalizations and interventions, and causing life-threatening complications which can significantly affect the quality of life in affected individuals. It is estimated that close to 6 million Americans suffer from gastroparesis which is more common in women than men. The economic impact of gastroparesis can be substantial, with studies reporting 11% of patients disabled due to their gastroparesis symptoms, while another 28.5% reported a loss of yearly income. Nausea without slow gastric emptying may be even more common and has been referred to by many names, including chronic unexplained nausea and vomiting (CUNV), gastroparesis-like syndrome (GLS), functional vomiting, and vomiting of unexplained etiology (VUE). Many of these patients can be classified as having functional dyspepsia (FD) which is a disorder that may affect 10% of the US population. Non-Invasive Vagal Nerve Stimulation (nVNS) Reduces Nausea Rescue Medication in Patients with Gastroparesis andRelated Disorders, with Additional Benefits on Multiple Other Associated Symptoms This pilot study (n=41) included patients =15 years of age with ongoing GP or FD symptoms for a period of =3 months. The focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
お知らせ • Oct 10electroCore, Inc. to Report Q3, 2023 Results on Nov 08, 2023electroCore, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023
お知らせ • Sep 28electroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress DisorderelectroCore, Inc. announced the publication of two peer reviewed publications supporting the use of gammaCore (non-invasive vagal nerve stimulation; nVNS) in patients with posttraumatic stress disorder (PTSD). The first paper entitled "Effect of transcutaneous cervical vagus nerve stimulation on declarative and working memory in patients with Posttraumatic Stress Disorder (PTSD): A pilot study" wasauthored by Tilendra Choudhary and the second, "Transcutaneous vagal nerve stimulation modulates stress-induced plasma ghrelin levels: A double-blind, randomized, sham-controlled trial" was written by Kasra Moazzami. Both studies were conducted at Emory University and were published in the peer reviewed Journal of Affective Stress Disorder. The prevalence of PTSD in the United States is estimated at 10-12% in women and 5-6% in men, and the prevalence in veterans can be twice as high. Ghrelin is a neuropeptide hypothesized to be involved in the stress response but also plays an important role in the regulation of appetite. Biomarkers that can be easily assessed can help identify likely responders to a specific therapy and are critical to improving the patient experience and decreasing health care costs. The results of this study showed that TCVNS, in conjunction with personalized traumatic scripts, resulted in lower ghrelin levels (265.2 +- 143.6 pg/ml vs 478.7 +- 349.2 pg/ml, P = 0.01). Additionally, after completing the public speaking and mental math tests, ghrelin levels were found to be lower in the group receiving TCVNS (293.3 +- 102.4 pg/ml vs 540.3 +- 203.9 pg/ml, P =0.009).2 Ghrelin may be involved in behaviors like stress-induced over-eating, suggesting future avenues of research into the potential for nVNS in the treatment of obesity and possibly stress-induced eating disorders.
お知らせ • Aug 24electroCore, Inc. Announces Dismissal of All Litigation Related to Its 2018 Initial Public OfferingelectroCore, Inc. announced that it has been completely vindicated in the securities class actions over the company’s 2018 initial public offering brought in the federal and state courts of New Jersey. The litigation has concluded without any finding of wrongdoing or liability, nor any payment, by electroCore. On July 13, 2023, District Judge Zahid N. Quraishi of the United States District for the District of New Jersey, dismissed the second amended class action complaint alleging violations of the Securities Act and the Securities Exchange Act. In a detailed opinion, Judge Quraishi considered each of the plaintiff’s allegations of misrepresentations and omissions in the prospectus for the IPO and in other public statements and filings in 2018-19 and held the plaintiff has not adequately pleaded any alleged untrue statement or that any allegedly omitted information rendered any factual statement untrue. Judge Quraishi also found that the plaintiff failed to adequately allege that electroCore intended to mislead or omit information. Judge Quraishi permitted the plaintiff thirty days to try to amend their complaint for a third time but warned that “while the Plaintiff can change the words of the Complaint, Plaintiff cannot change the words of the Prospectus.” Judge Quraishi’s dismissal followed the prior dismissal of the first amended complaint, also in a detailed opinion assessing each of plaintiff’s allegations, by District Judge Anne E. Thompson, on August 13, 2021. The plaintiff decided not to amend their complaint a third time and did not appeal the District Court’s ruling within the required time. Thus, the federal court litigation is over. This follows the termination earlier this year of litigation over the IPO and electroCore’s statements initiated in 2019 in the Somerset County, New Jersey Superior Court. That case was twice dismissed with prejudice, and on May 15, 2023, the Appellate Division of the New Jersey Superior Court unanimously affirmed the dismissal with prejudice. The time for further appeals in that case also has expired. Thus, the litigation over the initial public offering has been brought to a close with a complete vindication of electroCore, its directors and its management in their handling of the 2018 IPO.
お知らせ • Aug 11electroCore, Inc. Reiterates Revenue Guidance for the Year 2023electroCore, Inc. reiterated revenue guidance for the year 2023. The company reiterates its revenue guidance of $14.0 million to $15.0 million for calendar year 2023.
お知らせ • Aug 03electroCore, Inc. to Report Q2, 2023 Results on Aug 09, 2023electroCore, Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023
お知らせ • Jul 12Electrocore Provides Earnings Guidance for the Second Quarter and Full Fiscal Year 2023electroCore Provided earnings guidance for the Second Quarter and full fiscal year 2023 . For the quarter, Company,anticipates reporting record quarterly revenue of approximately $3,550,000 for the quarter ended June 30, 2023. This would represent approximately 65% growth over second quarter 2022 revenue of approximately $2,157,000For the year, Company reiterated its revenue guidance of $14.0 Million -$15.0 Million.
お知らせ • Jun 06electroCore, Inc., Annual General Meeting, Aug 04, 2023electroCore, Inc., Annual General Meeting, Aug 04, 2023, at 09:00 US Eastern Standard Time. Agenda: To elect one Class II director to the Board for a three-year term of office expiring at the 2026 Annual Meeting of Stockholders; and to ratify the selection of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.
お知らせ • May 05electroCore, Inc. Reiterates Revenue Guidance for the Year Ending December 31, 2023electroCore, Inc. reiterated revenue guidance for the year ending December 31, 2023. The Company reiterated its revenue guidance of $14.0 million to $15.0 million for the year ending December 31, 2023.
お知らせ • Jan 18electroCore, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2022electroCore, Inc. provided preliminary earnings guidance for the fourth quarter and full year of 2022. For the year, the company anticipates reporting record full year 2022 revenue of approximately $8.5 million. This would represent approximately 57% growth over full-year 2021 revenue of $5.5 million.For the quarter, the company's revenue is anticipated to be approximately $2.5 million, which would represent approximately 68% growth over fourth quarter of 2021.
お知らせ • Dec 26electroCore Receives a Determination Letter from Nasdaq Regarding Minimum Bid PriceOn December 20, 2022, electroCore, Inc. (the “Company”), received a determination letter (the “Letter”) from the staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company’s common stock, par value $0.001 per share (the “Common Stock”), has not achieved a minimum bid price of $1.00 per share for a minimum of 10 consecutive trading days, as required for continuing listing of the Common Stock on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The Company intends to timely request an appeal hearing before a Nasdaq Hearings Panel (the “Panel”). While the appeal process is pending, the potential suspension of trading of the Common Stock by Nasdaq will be stayed, a Form 25-NSE will not be filed with the Securities and Exchange Commission (the “SEC”), and the Common Stock will continue to trade on the Nasdaq Capital Market until the hearing process concludes and the Panel issues a written decision. The Company expects to be asked to furnish the Panel with a plan to regain compliance. As part of such plan, the Company is prepared to pursue stockholder authorization of a reverse stock split and make other commitments as necessary to regain compliance with the Bid Price Rule in order to avoid delisting of the Common Stock from the Nasdaq Capital Market. Pursuant to the Letter, if the Company does not timely request a hearing by 4:00 p.m. Eastern Time on December 27, 2022, the Common Stock will be delisted from the Nasdaq Capital Market, trading of the Common Stock will be suspended at the opening of business on December 29, 2022, and a Form 25-NSE will be filed with the SEC, which will remove the Common Stock from listing and registration on Nasdaq. There can be no assurance that the Panel will grant the Company’s request for a suspension of delisting or continued listing on the Nasdaq Capital Market. If the Common Stock ceases to be listed for trading on the Nasdaq Capital Market, the Company expects the Common Stock would be traded on one of the marketplaces of the OTC Markets Group. On December 23, 2022, the Company filed a definitive proxy statement on Schedule 14A with the SEC relating to a special meeting (the “ Special Meeting”) of stockholders of the Company currently scheduled to be held on February 13, 2023, at which the stockholders will consider and vote on a proposal to authorize the Board, in its discretion, to effect a reverse stock split of the Common Stock (the “ Reverse Stock Split Proposal”). The reverse stock split will not be effective unless and until the stockholders approve the Reverse Stock Split Proposal, and unless and until an amendment to the Company’s certificate of incorporation, as amended, to effect the reverse stock split is filed with the Secretary of State of the State of Delaware. There can be no assurance that the Company will not be delisted from Nasdaq before or after the stockholders have the opportunity at the Special Meeting to approve the Reverse Stock Split Proposal.
お知らせ • Dec 21electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, TruvagaelectroCore, Inc. announced the launch of a new wellness product offering called Truvaga(TM) for customers residing in the United States. Truvaga is a handheld non-invasive vagus nerve stimulator that utilizes proven technology to quickly and gently activate the vagus nerve. Stress affects every aspect of ives including sleep, memory, learning, weight, fitness and more. Truvaga offers a drug-free, simple, and convenient way to help reduce stress with just 2-minute sessions, day and night; no apps, batteries, chargers or phones are required.
お知らせ • Nov 04electroCore, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022electroCore, Inc. provided revenue guidance for the fourth quarter of 2022. For the fourth quarter of 2022, the company expects net revenue to be between $2.2 million and $2.3 million.
お知らせ • Oct 28electroCore, Inc. to Report Q3, 2022 Results on Nov 03, 2022electroCore, Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2022
お知らせ • Oct 16electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022electroCore, Inc. provided revenue guidance for the third quarter of 2022. The Company anticipates reporting third quarter 2022 revenue of approximately $1,976,000. This represents approximately 33% growth over the third quarter 2021 revenue of $1,487,000.
お知らせ • Sep 21electroCore, Inc., Annual General Meeting, Dec 02, 2022electroCore, Inc., Annual General Meeting, Dec 02, 2022.
お知らせ • Sep 08electroCore, Inc. Announces Publication of a Peer Reviewed Manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use DisorderelectroCore, Inc. announced the publication of a peer reviewed manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder: A Double-Blind, Randomized, Sham-Controlled Pilot Study in the journal, Brain Stimulation. The study, conducted with the support of Emory and Georgia Tech University, was sponsored by a grant from the National Institute on Drug Addiction (NIDA), part of the National Institutes of Health (NIH), through NIH Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative. Substance use is an escalating crisis in the United States, with opioid-related drug overdose deaths rising above 100,000 in 2021. The standard of care for treating opioid use disorder (OUD) is medication for opioid use disorder (MOUD), including opioid receptor agonists and antagonists. Yet, the barriers to care are high with only 11% of patients who have OUD receiving the MOUD they need. Additionally, OUD relapse is common amongst patients. As many as 70% of patients with OUD return to use without medication and 46% of patients on methadone, an opioid agonist medication, will relapse. Treatment with the opioid antagonist naltrexone requires an extended period of detoxification before initiation, which can be associated with withdrawal symptoms. Relapse during this period may be associated with an even higher risk of relapse-related overdose and death. New treatments are therefore necessary for managing withdrawal in the treatment of OUD. This double-blind, randomized, sham-controlled study of 21 patients with OUD found that nVNS reduced both the psychological and physiological symptoms of acute opioid withdrawal. In particular, statistically significant reductions in opioid withdrawal symptoms (-1.9 ± 3.7 vs. 0.4 ± 1.0; p=0.047), distress (-17.5 ± 26.5 vs. 2.2 ± 5.9; p=0.004), and pain (-0.8 ± 2.4 vs. 0.9 ± 1.0; p=0.045) were observed over the course of a 2-hour protocol for the nVNS group, in comparison to the sham stimulation group. This was accompanied by a statistically significant decrease in heart rate during active nVNS compared to sham stimulation, across all stimulations (-5.5 ± 3.5 bpm vs. -1.4 ± 2.3 bpm; 0=0.035).
お知らせ • Aug 06electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022electroCore, Inc. provided revenue guidance for the third quarter of 2022. FOr the quarter, the company expected net revenue to be approximately second quarter 2022 levels.
お知らせ • Jul 29electroCore, Inc. to Report Q2, 2022 Results on Aug 04, 2022electroCore, Inc. announced that they will report Q2, 2022 results After-Market on Aug 04, 2022
お知らせ • Jul 13electroCore, Inc. Provides Preliminary Unaudited Earnings Guidance for the Second Quarter of 2022electroCore, Inc. provided preliminary unaudited earnings guidance for the second quarter of 2022. For the quarter, the company expects revenue of more than $2,100,000. This represents at least an 11% increase over the first quarter 2022 revenue of $1,899,000 and approximately 65% growth over the second quarter 2021 revenue of $1,269,000.
お知らせ • Jul 08Electrocore, Inc. Announces Study of Gammacore Sapphire™ for the Treatment of Post-Covid SyndromeelectroCore, Inc. announced Mayo Clinic is initiating an investigator-initiated study to assess the efficacy of gammaCore Sapphire non-invasive vagus nerve stimulation (nVNS) in patients with post-COVID syndrome. Post-COVID syndrome, also known as Long COVID, is a collection of symptoms that persist greater than 28 days after the initial onset of symptoms of SARS-CoV-2 (COVID) infection1,2. These symptoms, such as headache, brain fog, fatigue and gastric distress can bear a striking resemblance to the “central sensitization syndromes,” a group that includes fibromyalgia, chronic fatigue syndrome, and postural orthostatic tachycardia syndrome (POTS). Post-COVID syndrome is likely to occur in upwards of 10% of the population who has been infected with COVID, likely affecting hundreds of millions across the world. The study entitled “Outcomes of treatment with non-invasive vagal nerve stimulation (nVNS) in post-COVID syndrome: A Pilot Study,” is a randomized, single-center, controlled trial enrolling up to 20 subjects recruited from the Post-COVID Care Clinic at Mayo Clinic in Rochester, Minnesota. Endpoints of the study include a number of clinical questionnaires including the Post-COVID Functional Status Score, as well as an analysis of blood samples for certain chemokines, and positron emission tomography-computed tomography (PET-CT) of the brain to evaluate brain metabolism. gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore is self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania continua in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
お知らせ • Jun 24electroCore Announces Listing Transfer to the Nasdaq Capital MarketelectroCore, Inc. announced that it has received approval from the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. The Company's common stock will continue to be traded under the symbol "ECOR" and trading of its common stock will be unaffected by this transfer. This transfer will be effective as of the opening of business on June 23, 2022. As previously disclosed, on December 20, 2021, the Company received a letter from Nasdaq notifying the Company of its noncompliance with Nasdaq Listing Rule 5450(a)(1) (the “Rule”) by failing to maintain a minimum closing bid price for its common stock on the Nasdaq Global Select Market of at least $1.00 per share for 30 consecutive business days. The Company was given a period of 180 calendar days, or until June 20, 2022, to regain compliance with the minimum closing bid price requirement. In response to not achieving the minimum closing bid price, the Company submitted an application to transfer its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market. In connection with the transfer, Nasdaq granted the Company a second period of 180 calendar days, or until December 19, 2022, to regain compliance with the minimum closing bid price requirement for continued listing by achieving a closing bid price on Nasdaq of at least $1.00 per share for 10 consecutive business days. Nasdaq granted the additional 180-day compliance period as the Company continues to meet the listing requirements of the Nasdaq Capital Market with the exception of the minimum closing bid price requirement. The Company intends to continue to actively monitor its compliance with the minimum closing bid price requirement and, as appropriate, will consider available options to resolve any deficiencies and regain compliance.
Recent Insider Transactions • Jun 17Co-Founder recently bought €53k worth of stockOn the 13th of June, Joseph Errico bought around 100k shares on-market at roughly €0.53 per share. This was the largest purchase by an insider in the last 3 months. This was Joseph's only on-market trade for the last 12 months.
お知らせ • May 26Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain CenterselectroCore, Inc. announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator will be available for purchase through many of the more than 130 National Spine and Pain Centers affiliated locations across the United States for patients suffering from pain associated with different forms of primary headache.
Reported Earnings • May 06First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.11 loss in 1Q 2021)First quarter 2022 results: US$0.079 loss per share. Revenue: US$1.90m (up 58% from 1Q 2021). Net loss: US$5.58m (loss widened 3.7% from 1Q 2021). Over the next year, revenue is forecast to grow 64%, compared to a 11% growth forecast for the industry in Germany.
お知らせ • May 06electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2022electroCore, Inc. provided earnings guidance for the second quarter of 2022. For the period, the company expects net revenue to be at least $1.9 million.
Board Change • Apr 27High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Director Tricia Wilber was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 22electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in NeurologyelectroCore, Inc. announced that Frontiers in Neurology has published results from an investigator-initiated trial, SAVIOR-1, a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore Sapphire™ in patients admitted to the hospital for treatment of COVID-19. The SAVIOR-1 trial was conducted by principal investigator Dr. Carlos Tornero, Head of the Department of Anesthesiology, Resuscitation and Pain Therapeutics of the Hospital Clínico Universitario de Valencia, Spain, between April 2020 and February 2021. The trial targeted patients over 18 years of age and enrolled 110 patients, randomly assigned, with 55 patients in each group. Of the 110 patients, 97 patients (47 in the nVNS treatment group, 50 in the control group) provided baseline demographic and medical history data and were the evaluable population. The study evaluated the safety and feasibility of nVNS when administered in addition to the then-standard of care in patients hospitalized with active SARS-CoV-2 infection compared with the standard of care alone. The study identified significant treatment differences for certain biomarkers of inflammation. Decreases from baseline in C-reaction protein (CRP) levels were significantly greater in the nVNS treatment group as compared to the control group throughout the five-day period combined (p=0.011) and on day 5 compared to the day 1 baseline period alone (p=0.015). On day 1, CRP levels were highly elevated for 90% of all subjects, but by days 3 and 5, the percentage of subjects with normal CRP levels improved markedly in the nVNS group with day 3 CRP levels at 17.9% vs. 52.2% in the control (p=0.010). Additionally, the nVNS group had a significantly greater decrease from baseline in procalcitonin level at day 5 (p=0.012) as compared to the control group. Increased levels of CRP, procalcitonin, and d-dimer have all been reported to be associated with more severe disease and the lower levels of these markers in the nVNS treated group may represent the initial impact of nVNS therapy to potentially improve the course of a patients’ COVID-19 symptoms. nVNS was well tolerated with no major device-related adverse events and the therapy was administered three times daily to most patients as outlined in the study protocol.
お知らせ • Apr 13electroCore, Inc. Provides Unaudited Preliminary Revenue Guidance for the First Quarter of 2022electroCore, Inc. provided unaudited preliminary revenue guidance for the first quarter of 2022. The Company anticipates first quarter 2021 revenue from product sales will be approximately $1.9 million. This represents an approximately 27% increase over fourth quarter 2021 revenue of $1.5 million and approximately 60% growth over first quarter 2021 revenue of $1.2 million.
Board Change • Apr 02High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Director Tricia Wilber was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 12Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.29 loss per share (up from US$0.60 loss in FY 2020). Revenue: US$5.45m (up 56% from FY 2020). Net loss: US$17.2m (loss narrowed 27% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 67%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
お知らせ • Mar 06electroCore, Inc. to Report Q4, 2021 Results on Mar 10, 2022electroCore, Inc. announced that they will report Q4, 2021 results After-Market on Mar 10, 2022
お知らせ • Feb 02electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative IleuselectroCore, Inc. announced enrollment has been completed for the TRANSIT study of non-invasive vagal nerve stimulation (nVNS) to reduce ileus after colorectal surgery. This randomized, participant blinded, sham-controlled study is being sponsored by the United Kingdom’s National Institute for Health Research (NIHR). The 97-patient study is led by Dr. Stephen Chapman, Clinical Research Fellow in the University of Leeds School of Medicine. The study is conducted at St. James Hospital in Leeds, England and Bradford Royal Infirmary in Bradford, England. Ileus occurs in 10-20% of patients who have undergone elective colorectal surgery. Ileus is a distressing condition characterized by abdominal distension, persistent vomiting, and delayed return of bowel function after surgery. For patients, it prolongs the length of hospital stays and increases the risk of serious complications such as pneumonia and venous thromboembolic events. For healthcare systems, ileus increases per-patient costs by up to 71%, particularly those associated with nursing care, laboratory investigations, and medications. Clinical endpoints in the TRANSIT study include the number of postoperative days to first flatus, first stool, first oral intake, hospital discharge, and the GI-2 composite outcome, a common clinical measure of return of bowel function. The amount of daily oral morphine equivalent requirements, as well as a number of safety and feasibility outcomes to inform potential future clinical research and use, will also be assessed. Study results are expected later this year and will be presented at an appropriate medical congress.
お知らせ • Jan 19electroCore, Inc. Provides Revenue Guidance for the Full Year of 2021electroCore, Inc. provided revenue guidance for the full year of 2021. The company anticipates full-year 2021 revenue will be approximately $5.5 million. This would represent an approximately 55% increase over full-year 2020 revenue of $3.5 million.
お知らせ • Jan 13+ 1 more updateelectroCore, Inc. Announces Publication of Premium II Trial of Gammacore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of MigraineelectroCore, Inc. announced the publication of a peer-reviewed paper, entitled Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial in Cephalalgia, the official journal of the International Headache Society (IHS). The paper reports the results of a randomized, double-blind, sham-controlled trial conducted at twenty-seven sites across the United States. Originally designed and powered to randomize 400 patients, the study was closed early due to COVID-19 after enrolling 231 subjects. The results of the study showed a decrease in the number of monthly headache days of 4.6 vs. -3.0 for sham (p=0.05) with 44.87% of subjects in the gammaCore group having greater than a 50% reduction in the number of migraine days per month compared with 26.81% for the sham group (p=0.05). Quality of life, as measured by the HIT-6 (Headache Impact scale), improved by -4.9 points vs. -2.3 for sham (p<0.05). In the subpopulation of patients diagnosed with migraine with aura, the number of headache days decreased by 5.5 days in the nVNS group compared with 2.7 in the sham group (p=0<0.05), a therapeutic gain of >100% compared to sham. These findings are consistent with previous reports on the mechanisms of action that suggest nVNS may be particularly effective in patients with migraine with aura.
Reported Earnings • Nov 06Third quarter 2021 earnings released: US$0.057 loss per share (vs US$0.10 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$1.49m (up 38% from 3Q 2020). Net loss: US$3.99m (loss narrowed 11% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
お知らせ • Sep 15electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania ContinuaelectroCore, Inc. announced that on September 10, 2021 the company received Section 510(k) clearance from the United States Food and Drug Administration (FDA) of the company’s submission to expand the label of gammaCore nVNS to include the treatment of Paroxysmal Hemicrania (PH) and Hemicrania Continua (HC) in adults. PH and HC are both rare forms of trigeminal autonomic cephalalgias (TAC), that are typically debilitating and difficult to treat. The most common type of TAC is cluster headache. gammaCore is also indicated for both the acute and preventative treatment of cluster headache, where it is considered a first-line treatment option. The label expansion was based on data collected from multiple clinical audits and case series/case reports that included patients with PH or HC. These included a total of 14 patients with PH and 19 patients with HC. 79% of the patients experienced clinically meaningful benefits from gammaCore for each indication, including decreases in the severity of persistent pain and/or reductions in the frequency, severity, and/or duration of exacerbations or attacks. Many subjects reported more than one clinical benefit. There were no serious or unexpected adverse events reported.
Reported Earnings • Aug 09Second quarter 2021 earnings released: US$0.06 loss per share (vs US$0.13 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$1.27m (up 69% from 2Q 2020). Net loss: US$2.89m (loss narrowed 39% from 2Q 2020).
お知らせ • Jul 15electroCore, Inc. Announces Revenue Guidance for the Second Quarter of 2021electroCore, Inc. announced revenue guidance for the second quarter of 2021. The company anticipates that second quarter 2021 revenue will be approximately $1.3 million.
お知らせ • Jul 01electroCore, Inc. has completed a Follow-on Equity Offering in the amount of $18 million.electroCore, Inc. has completed a Follow-on Equity Offering in the amount of $18 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 18,000,000 Price\Range: $1 Discount Per Security: $0.08
お知らせ • Jun 03electroCore, Inc. Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’S Disease PatientselectroCore, Inc. announced the publication of a peer-reviewed paper, entitled “Non-Invasive Vagus Nerve Stimulation Improves Clinical and Molecular Biomarkers of Parkinson’s Disease in Patients with Freezing of Gait” in the journal NPJ Parkinson’s Disease. The paper reports the results of a randomized, double-blind, sham-controlled crossover trial conducted at the Institute of Neurosciences in Kolkata, India in collaboration with the Faculty of Medical Sciences at Newcastle University in England using gammaCore SapphireTM. The study was funded by the Institute of Neurosciences, Kolkata, India. Neurological disorders are now the leading source of disability in the world, and Parkinson’s disease is the fastest-growing of these disorders. As populations age and life expectancy increases, the number of individuals with Parkinson’s disease and the duration of the disease will increase, leading to more patients with advanced Parkinson’s disease. To address this burden, primary prevention strategies based on the underlying causes of Parkinson’s disease and more effective symptomatic treatments are needed. The study, which enrolled thirty-six subjects, was undertaken to explore the safety, feasibility and efficacy of self-administered non-invasive vagus nerve stimulation (nVNS) in the treatment of gait and other motor symptoms in Parkinson’s disease (PD) patients. In a subgroup of study patients, levels of selected neurotrophins, markers of inflammation and oxidative stress were measured in blood before and after nVNS. Vagus Nerve Stimulation (VNS) has been found to be beneficial in improving locomotion in a rat model of PD,3 and two independent preliminary studies found improvement in gait in patients with PD after a single application of cervical nVNS. The study provides preliminary evidence supporting the safety and efficacy of nVNS in treating motor and non-motor symptoms of PD. Patients were satisfied with the treatment and the majority were able to self-administer nVNS. Adverse events were infrequent, non-serious, and similar across both Active and Sham groups. Significant increases in velocity (p=0.003), step length (p=0.007), and a reduction in stance time (p=0.001) were seen in the nVNS treated group compared to sham stimulation, indicating that PD patients were walking not only with a faster pace but also with improved rhythm. Other gait parameters also showed significant improvement from baseline in all five domains, specifically after nVNS treatment, suggesting that nVNS may result in an overall improvement in the quality of gait in PD patients. Treatment with nVNS significantly reduced TNF-a levels (p<0.05) and increased concentrations of reduced glutathione (p<0.05), which are both markers of inflammation in PD patients. Brain Derived Neurotrophic Growth Factors, which are reduced in PD, were significantly increased by nVNS (p<0.05) suggesting a possible disease modifying effect.
お知らせ • May 25electroCore, Inc. Develops Non-Drug and Non-Invasive Alternative to Pharmaceuticals That Safely and Effectively Stimulates the Vagus Nerve to Communicate with the Brain and Help Optimize the Body’s Own Ability to Control Problems Impacting Its HealthelectroCore, Inc. developed a non-drug and non-invasive alternative to pharmaceuticals that safely and effectively stimulates the vagus nerve to communicate with the brain and help optimize the body’s own ability to control problems impacting its health. While vagus nerve stimulation (VNS) has been available for decades, electroCore has transformed the industry with non-invasive vagus nerve stimulation (nVNS) therapy which taps into the power and potential of the vagus nerve via a portable device. Implanted Vagus Nerve Stimulation (iVNS), which involves the surgical implantation of a device, was one of the first major breakthroughs highlighting how electrical stimulation could be used to treat conditions such as depression, epilepsy, infectious disease, and heart disease. In 2008, electroCore joined this medical exploration and two years later created a non-invasive way of delivering VNS therapy. Between 2011 and 2017, nVNS received CE Marks, which means it fulfilled the requirements of relevant European product directives in addition to performance and safety standards, for the treatment of multiple conditions in neurology, psychiatry, and gastroenterology. In 2017, electroCore’s nVNS received its first FDA clearance for the acute treatment of episodic cluster headache. Since then, electroCore’s game changing nVNS therapy received four additional FDA clearances as well as growing acknowledgement from health care providers and patients as a front-line, non-drug option for the treatment and prevention of migraine and cluster headache. The creation of a safe, patient-controlled way of activating the vagus nerve has opened the door for the research and clinical community to study the vagus nerve’s potential to treat several conditions more easily and safely. At the forefront of medicine, electroCore and other organizations are expanding research on the vagus nerve with clinical studies of nVNS’s effectiveness on conditions including COVID-19, post-traumatic headache, traumatic brain injury, post-traumatic stress disorder, Parkinson’s disease, epilepsy, stroke, sub-arachnoid hemorrhage and addiction as well as a number of gastrointestinal and inflammatory conditions.
Reported Earnings • May 09First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.27 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$1.20m (up 64% from 1Q 2020). Net loss: US$5.38m (loss narrowed 32% from 1Q 2020).
お知らせ • May 07electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2021electroCore, Inc. provided earnings guidance for the second quarter of 2021. For the second quarter of 2021, the company expects net revenue to exceed $1.2 million and net cash usage, exclusive of financing activities, to approximate First Quarter 2021 levels.
お知らせ • Apr 27electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related DisorderselectroCore, Inc. announced that Johns Hopkins University School of Medicine is starting an investigator-initiated trial of non-invasive vagus nerve stimulation (nVNS) using the Company’s proprietary gammaCore device to treat symptomatic exacerbation of nausea in patients with gastroparesis and related disorders (NCT04857281). Many gastrointestinal disorders can cause nausea and vomiting, of which the most well-known is gastroparesis, a digestive disorder in which the stomach empties slowly. The symptoms of gastroparesis can range from mild to severe, requiring prolonged hospitalizations and interventions, and causing life-threatening complications which can significantly affect the quality of life in affected individuals. It is estimated that close to 6 million Americans suffer from gastroparesis which is more common in women than men.2 The economic impact of gastroparesis can be substantial, with studies reporting 11% of patients disabled due to their gastroparesis symptoms, while another 28.5% reported a loss of yearly income. Nausea without slow gastric emptying may be even more common and has been referred to by many names, including chronic unexplained nausea and vomiting (CUNV), gastroparesis-like syndrome (GLS), functional vomiting, and vomiting of unexplained etiology (VUE). Many of these patients can be classified as having functional dyspepsia (FD) which is a disorder that may affect 10% of the US population.
お知らせ • Apr 14ElectroCore, Inc. Provides Revenue Guidance for the First Quarter of 2020electroCore, Inc. provided revenue guidance for the first quarter of 2020. For the quarter, the company anticipates that first quarter 2021 revenue will be more than $1.1 million, representing greater than 50% growth over first quarter 2020 revenue of $0.7 million and greater than 20% growth over fourth quarter 2020 revenue of $0.9 million.
Reported Earnings • Mar 16Full year 2020 earnings released: US$0.60 loss per share (vs US$1.54 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$3.50m (up 46% from FY 2019). Net loss: US$23.5m (loss narrowed 48% from FY 2019).
お知らせ • Mar 05electroCore, Inc. to Report Q4, 2020 Results on Mar 11, 2021electroCore, Inc. announced that they will report Q4, 2020 results After-Market on Mar 11, 2021
お知らせ • Mar 01electroCore, Inc. Announces Exclusive Distribution Agreement with Medistar2 PTY Limited Following Regulatory Approval in AustraliaelectroCore, Inc. announced that it has entered into an agreement with Medistar2 PTY Limited (“Medistar”) whereby Medistar will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Australia, supplying therapy to patients suffering with primary headache disorders. The announcement follows the granting of regulatory approval from the Australian Therapeutic Goods Administration (TGA) for the promotion and sale of the gammaCore Sapphire family of products. The initial term of the agreement is three years and contains customary terms and conditions, including minimum purchase commitments. Medistar will be officially launching gammaCore Sapphire at the 2021 ANZHS Headache Annual Scientific Meeting, which will be held on March 13-14.
お知らせ • Feb 25Non-Invasive Vagus Nerve Stimulation (Nvns) Enters New Stage of Covid-19 Research of electrocore, IncelectroCore, Inc. announced the completion of patient enrollment in SAVIOR-1, or “Prospective, Randomized, Controlled Study to Evaluate the Effect of Non-Invasive Electrical Vagus Nerve Stimulation on Respiratory Symptoms due to COVID-19.” This study was supported in part by electroCore. Closing enrollment for this study is an important step to better understanding the clinical benefit of non-invasive vagus nerve stimulation (nVNS) and how it can help patients suffering from COVID-19 respiratory distress. gammaCore SapphireTM CV (nVNS) received Emergency Use Authorization from the FDA in July of 2020 to treat patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow.